,label_name,cluster
0,[Gene]_BRAF,7
1,[Variant]_BRAF:AKAP9-BRAF,7
2,[Gene]_BRCA1,6
3,[Variant]_BRCA1:MUTATION,1
4,[Gene]_PIK3CA,1
5,[Disease]_Epithelial Ovarian Cancer,0
6,[Gene]_KRAS,3
7,[Gene]_EGFR,3
8,[Gene]_BRCA2,1
9,[Variant]_BRCA2:MUTATION,4
10,[Gene]_CCNE1,5
11,[Variant]_CCNE1:AMPLIFICATION,1
12,[Gene]_MTOR,0
13,[Disease]_T-cell Acute Lymphoblastic Leukemia,6
14,[Gene]_NT5C2,1
15,[Gene]_DNMT3A,0
16,[Variant]_EGFR:AMPLIFICATION,1
17,[Disease]_Barrett's Adenocarcinoma,1
18,[Disease]_Cervical Squamous Cell Carcinoma,0
19,[Variant]_EGFR:COPY NUMBER VARIATION,2
20,[Variant]_EGFR:OVEREXPRESSION,4
21,[Disease]_Brain Glioblastoma Multiforme,1
22,[Gene]_ERG,2
23,[Variant]_ERG:EWSR1-ERG,2
24,[Variant]_ERG:TMPRSS2-ERG,4
25,[Gene]_FGFR3,4
26,[Variant]_FGFR3:Y375C,2
27,[Gene]_FLI1,1
28,[Variant]_FLI1:EWSR1-FLI1,3
29,[Gene]_FOXL2,0
30,[Variant]_FOXL2:C134W,2
31,[Gene]_DICER1,1
32,[Disease]_Ovarian Granulosa Cell Tumor,0
33,[Gene]_IDH2,5
34,[Variant]_IDH2:R172,2
35,[Gene]_IKZF1,4
36,[Variant]_IKZF1:DELETION,2
37,[Gene]_ABL1,4
38,[Disease]_B-lymphoblastic Leukemia/lymphoma,5
39,[Gene]_TP53,6
40,[Gene]_KIT,3
41,[Variant]_KIT:M541L,2
42,[Variant]_KIT:V560DEL,3
43,[Disease]_Thymic Carcinoma,1
44,[Variant]_KRAS:G13,5
45,[Variant]_KRAS:Q61,1
46,[Gene]_IDH1,0
47,[Disease]_Oligodendroglioma,6
48,[Gene]_MGMT,1
49,[Gene]_NCOA3,2
50,[Variant]_NCOA3:AMPLIFICATION,2
51,[Variant]_NCOA3:OVEREXPRESSION,6
52,[Gene]_NOTCH1,2
53,[Variant]_NOTCH1:MUTATION,0
54,[Variant]_NOTCH1:P2514FS,6
55,[Gene]_HRAS,0
56,[Disease]_Thyroid Gland Follicular Carcinoma,5
57,[Gene]_GNAS,0
58,[Gene]_PAX8,6
59,[Gene]_NRAS,1
60,[Variant]_PAX8:PAX8-PPARG,3
61,[Gene]_MET,1
62,[Disease]_Renal Cell Carcinoma,4
63,[Variant]_MET:Amplification,6
64,[Variant]_MTOR:Q2223K,6
65,"[Variant]_MTOR:L1460P, L2209V, L2427Q",2
66,[Gene]_BAP1,0
67,[Gene]_KLLN,2
68,[Gene]_HIF1A,1
69,[Gene]_EPAS1,0
70,[Gene]_VHL,1
71,[Gene]_FBXW7,1
72,[Gene]_CCND1,1
73,[Gene]_CDKN2B,0
74,[Gene]_CDKN2A,1
75,[Gene]_FLT3,4
76,[Gene]_B4GALT1,1
77,[Gene]_ALK,2
78,[Gene]_HMOX1,1
79,[Gene]_PBRM1,0
80,[Gene]_PGR,0
81,[Variant]_PGR:EXPRESSION,3
82,[Disease]_Estrogen-receptor Positive Breast Cancer,4
83,[Drug]_Tamoxifen,0
84,[Disease]_Breast Cancer,0
85,"[Drug]_Exemestane,Tamoxifen",3
86,[Variant]_PIK3CA:AMPLIFICATION,0
87,[Gene]_HSPH1,7
88,[Disease]_Gastric Adenocarcinoma,3
89,[Gene]_PBK,3
90,[Gene]_PSMB8,0
91,[Gene]_ERBB2,0
92,[Gene]_CXCR4,1
93,[Gene]_DNMT1,2
94,[Gene]_RPS6,1
95,[Gene]_TYMS,1
96,[Gene]_EIF4EBP1,1
97,[Gene]_ATM,2
98,[Gene]_PTEN,1
99,[Gene]_FGFR1,7
100,[Variant]_PTEN:DELETION,0
101,[Disease]_Prostate Adenocarcinoma,4
102,[Variant]_PTEN:LOSS,0
103,[Drug]_Temsirolimus,3
104,[Disease]_Endometrial Cancer,4
105,[Disease]_Renal Carcinoma,3
106,[Disease]_Prostate Cancer,3
107,[Gene]_SMAD4,6
108,[Variant]_SMAD4:MUTATION,2
109,[Disease]_Pancreatic Adenocarcinoma,1
110,[Variant]_BRCA1:Oncogenic Mutations,2
111,[Variant]_BRCA2:Oncogenic Mutations,3
112,[Gene]_NRG1,4
113,[Gene]_RB1,3
114,[Gene]_SMARCA4,1
115,[Variant]_SMARCA4:MUTATION,7
116,[Disease]_Small-cell Carcinoma Of The Ovary Of Hypercalcemic Type,6
117,[Variant]_SMARCA4:INACTIVATING MUTATION,1
118,[Gene]_TERT,1
119,[Variant]_TERT:AMPLIFICATION,4
120,[Disease]_Acral Lentiginous Melanoma,1
121,[Variant]_TERT:PROMOTER MUTATION,7
122,[Disease]_Skin Melanoma,3
123,[Gene]_B2M,4
124,[Gene]_JAK2,1
125,[Gene]_JAK1,3
126,[Gene]_GNAQ,0
127,[Gene]_RAF1,7
128,[Gene]_EZH2,7
129,[Gene]_NF1,7
130,[Gene]_CDK4,5
131,[Gene]_HLA-DRA,3
132,[Variant]_TP53:DELETERIOUS MUTATION,7
133,[Variant]_TP53:MUTATION,2
134,[Gene]_AXL,2
135,[Disease]_Esophagus Squamous Cell Carcinoma,4
136,[Gene]_AURKA,7
137,[Gene]_MDM2,2
138,[Disease]_Myeloid Neoplasm,6
139,[Variant]_TP53:TRUNCATING MUTATION,6
140,[Gene]_TTF1,2
141,[Variant]_TTF1:AMPLIFICATION,0
142,[Variant]_ERBB2:AMPLIFICATION,2
143,[Gene]_ERBB3,7
144,[Disease]_Her2-receptor Positive Breast Cancer,2
145,[Gene]_BIRC5,4
146,[Disease]_Esophagogastric Cancer,0
147,[Drug]_Trastuzumab,7
148,[Variant]_ERBB2:Amplification,1
149,[Disease]_Scrotum Paget's Disease,2
150,[Disease]_Endometrial Serous Adenocarcinoma,2
151,[Disease]_Lung Adenocarcinoma,3
152,[Disease]_Lung Non-small Cell Carcinoma,3
153,[Gene]_CHEK2,1
154,[Variant]_CHEK2:LOSS-OF-FUNCTION,3
155,"[Drug]_Gemcitabine,Trametinib",7
156,[Gene]_CDK12,6
157,[Variant]_CDK12:LOSS-OF-FUNCTION,1
158,[Disease]_Ovarian Serous Carcinoma,1
159,[Gene]_MAP2K1,0
160,[Gene]_CD274,6
161,[Disease]_Peripheral T-cell Lymphoma,7
162,[Variant]_NT5C2:R367Q,7
163,[Disease]_Childhood B-cell Acute Lymphoblastic Leukemia,1
164,"[Drug]_Mercaptopurine,Thioguanine",2
165,[Disease]_Childhood Acute Lymphocytic Leukemia,0
166,[Variant]_NT5C2:K359Q,3
167,[Variant]_NT5C2:D407A,3
168,"[Drug]_Nelarabine,Arabinosylguanine",7
169,[Variant]_ABL1:BCR-ABL F317L,0
170,[Variant]_TP53:DNA BINDING DOMAIN MUTATION,1
171,[Gene]_GAS6,1
172,[Disease]_Oral Squamous Cell Carcinoma,1
173,[Disease]_Lung Cancer,7
174,"[Drug]_Multikinase Inhibitor AEE788,Gefitinib",7
175,[Drug]_Rociletinib,5
176,[Variant]_ATM:S2289*,7
177,[Variant]_ATM:N2875H,7
178,[Gene]_NF2,7
179,[Variant]_NF2:Y177FS,7
180,[Disease]_Peritoneal Mesothelioma,2
181,[Disease]_Ovarian Cancer,3
182,"[Drug]_Cisplatin,Carboplatin",7
183,[Disease]_Triple-receptor Negative Breast Cancer,7
184,[Gene]_PDGFRA,1
185,[Variant]_PDGFRA:V561A,2
186,[Variant]_TERT:C228T,0
187,[Gene]_XRCC1,1
188,[Variant]_XRCC1:R194W,2
189,"[Drug]_Gemcitabine,Vinorelbine,Docetaxel",1
190,[Gene]_GSTP1,4
191,[Variant]_GSTP1:DELETION,7
192,[Disease]_Ovarian Carcinoma,0
193,"[Drug]_Cisplatin,Carboplatin,Paclitaxel",7
194,[Gene]_BIRC7,1
195,[Variant]_BIRC7:AMPLIFICATION,4
196,[Disease]_Colon Cancer,3
197,[Gene]_POU5F1,6
198,[Disease]_Bladder Cancer,1
199,[Drug]_Cisplatin,5
200,[Variant]_ERCC2:Oncogenic Mutations,3
201,[Disease]_Transitional Cell Carcinoma,3
202,[Disease]_Cervix Carcinoma,7
203,[Disease]_Cancer,0
204,[Disease]_Head And Neck Squamous Cell Carcinoma,1
205,[Disease]_Bladder Carcinoma,0
206,[Disease]_Osteosarcoma,1
207,[Variant]_EGFR:EXON 4 DELETION,4
208,[Variant]_KRAS:RS61764370,1
209,"[Drug]_Carboplatin,Paclitaxel",1
210,[Gene]_ERCC5,1
211,[Variant]_ERCC5:RS751402,4
212,[Disease]_Parietal Lobe Ependymoma,3
213,[Variant]_KIT:3' UTR MUTATION,1
214,[Variant]_EZH2:INTRON 6 MUTATION,7
215,[Gene]_MTHFR,1
216,[Variant]_MTHFR:A222V,7
217,[Disease]_Rectum Cancer,4
218,[Drug]_Fluorouracil,1
219,[Disease]_Colorectal Cancer,2
220,[Disease]_Stomach Cancer,7
221,[Variant]_GSTP1:I105V,4
222,[Drug]_FOLFOX Regimen,0
223,[Gene]_ABCG2,1
224,[Variant]_ABCG2:Q141K,1
225,[Variant]_XRCC1:Q399R,7
226,[Disease]_Cervical Cancer,7
227,[Gene]_SPHK1,2
228,"[Drug]_Carboplatin,Cisplatin",4
229,[Gene]_ABCB1,1
230,[Variant]_ABCB1:S893T,7
231,[Variant]_ABCB1:I1145I,1
232,[Gene]_ERCC2,7
233,[Variant]_ERCC2:K751Q,7
234,[Variant]_TYMS:5' TANDEM REPEAT,0
235,"[Drug]_Fluorouracil,Irinotecan",5
236,[Gene]_LRP1B,2
237,[Variant]_LRP1B:EXON 12-22 DELETION,0
238,[Variant]_FGFR1:AMPLIFICATION,6
239,[Variant]_FGFR1:Amplification,5
240,[Disease]_Lung Squamous Cell Carcinoma,1
241,[Gene]_NFE2L2,7
242,[Variant]_FGFR1:EXPRESSION,1
243,[Gene]_ROS1,2
244,[Variant]_ROS1:REARRANGEMENT,7
245,[Variant]_MET:AMPLIFICATION,4
246,[Drug]_Onartuzumab,0
247,[Gene]_ATR,7
248,[Variant]_ATR:I774FS,0
249,[Variant]_AKT1:E17K,5
250,[Gene]_AKT1,7
251,[Gene]_POLE,0
252,[Gene]_FGFR2,1
253,[Gene]_MRE11,4
254,[Gene]_RIT1,4
255,"[Drug]_Fluorouracil,Platinum Compound,Cetuximab",0
256,[Disease]_Glioblastoma,7
257,[Drug]_Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,4
258,[Variant]_CDKN2A:p16 EXPRESSION,4
259,[Gene]_RET,0
260,[Variant]_RET:KIF5B-RET,1
261,[Variant]_RET:Fusions,7
262,[Drug]_Vandetanib,6
263,[Disease]_Non-Small Cell Lung Cancer,7
264,[Variant]_HRAS:G13D,7
265,[Variant]_HRAS:MUTATION,0
266,"[Drug]_Binimetinib,MTOR Kinase Inhibitor AZD8055,Selumetinib,Everolimus,MEK Inhibitor PD0325901",1
267,[Variant]_CD274:EXPRESSION,7
268,"[Drug]_Nivolumab,Pembrolizumab",6
269,[Disease]_Melanoma,1
270,[Variant]_MTOR:MUTATION,5
271,"[Drug]_Pazopanib,Everolimus",1
272,[Gene]_AKT2,1
273,[Variant]_AKT2:EXPRESSION,6
274,[Drug]_Uprosertib,7
275,[Drug]_Capivasertib,7
276,"[Drug]_Pictilisib,Akt Inhibitor MK2206",6
277,[Drug]_PI3Kbeta Inhibitor AZD8186,1
278,[Variant]_MTOR:H1968Y,0
279,"[Drug]_PI3K/BET Inhibitor LY294002,Capivasertib",7
280,"[Drug]_Buparlisib,Carboplatin,Paclitaxel",0
281,[Variant]_NF2:K159FS*16,0
282,[Variant]_EGFR:S492R,0
283,[Variant]_FBXW7:MUTATION,0
284,[Variant]_SMAD4:UNDEREXPRESSION,5
285,[Variant]_MTOR:P2213S,7
286,[Variant]_BRAF:AGK-BRAF,7
287,[Variant]_BRAF:PAPSS1-BRAF,2
288,[Variant]_BRAF:TRIM24-BRAF,6
289,[Variant]_BRAF:L597R,7
290,[Variant]_ERBB3:OVEREXPRESSION,2
291,[Gene]_NT5E,7
292,[Variant]_NT5E:OVEREXPRESSION,3
293,[Variant]_EZH2:OVEREXPRESSION,7
294,[Disease]_Acute Myeloid Leukemia,7
295,[Drug]_GSK321,0
296,[Gene]_MYD88,1
297,[Variant]_MYD88:OVEREXPRESSION,6
298,[Variant]_MET:EXON 14 SKIPPING MUTATION,7
299,[Variant]_PIK3CA:P471L,1
300,[Disease]_Merkel Cell Carcinoma,1
301,[Drug]_Idelalisib,7
302,[Variant]_RET:EXPRESSION,7
303,[Variant]_RIT1:OVEREXPRESSION,6
304,[Variant]_RIT1:MUTATION,1
305,"[Drug]_Pictilisib,Selumetinib",2
306,[Gene]_MYCN,1
307,[Variant]_MYCN:AMPLIFICATION,7
308,[Disease]_Neuroblastoma,0
309,[Drug]_FACT Complex-targeting Curaxin CBL0137,0
310,[Gene]_SMO,6
311,[Variant]_SMO:D473H,7
312,[Gene]_CTNNB1,7
313,[Disease]_Medulloblastoma,6
314,[Gene]_PTCH1,1
315,"[Disease]_Skin Cancer, Non-Melanoma",1
316,[Drug]_Vismodegib,6
317,[Variant]_PTCH1:Truncating Mutations,7
318,[Disease]_Basal Cell Carcinoma,7
319,[Variant]_SMO:MUTATION,6
320,"[Drug]_PSI,Arsenic Trioxide",0
321,[Variant]_PTCH1:MUTATION,0
322,[Disease]_Embryonal Tumor,1
323,[Drug]_Sonidegib,5
324,[Variant]_PTCH1:LOH,7
325,[Gene]_STK11,1
326,[Variant]_STK11:EXON 1-2 MUTATION,1
327,[Variant]_STK11:UNDEREXPRESSION,1
328,[Drug]_SB202190,7
329,[Gene]_SYK,4
330,[Variant]_SYK:OVEREXPRESSION,7
331,[Drug]_Pictilisib,4
332,[Disease]_Oropharynx Cancer,6
333,[Drug]_AKTi-1/2,7
334,[Variant]_ALK:EML4-ALK L1152R,1
335,[Variant]_ALK:EML4-ALK G1269A,1
336,[Gene]_ERBB4,0
337,[Variant]_ERBB4:MUTATION,7
338,[Variant]_PIK3CA:MUTATION,4
339,[Drug]_Cabozantinib,6
340,"[Variant]_MET:D1010, Exon 14 deletion, Exon 14 splice mutation, Y1003",0
341,[Disease]_Thyroid Gland Medullary Carcinoma,7
342,[Disease]_Uveal Melanoma,1
343,[Variant]_EGFR:VIII,1
344,[Variant]_EGFR:Exon 19 insertion,0
345,[Drug]_Afatinib,1
346,[Variant]_EGFR:L718V,3
347,[Variant]_EGFR:L747P,2
348,[Variant]_EGFR:A763_Y764insFQEA,0
349,[Variant]_EGFR:L861Q,1
350,[Variant]_EGFR:S768I,1
351,"[Variant]_EGFR:Exon 19 deletion, L858R",0
352,[Variant]_EGFR:G719,5
353,[Variant]_EGFR:E709_T710delinsD,0
354,[Variant]_EGFR:Kinase Domain Duplication,1
355,[Disease]_Pancreatic Ductal Adenocarcinoma,7
356,[Disease]_Mucinous Adenocarcinoma,1
357,[Disease]_Cholangiocarcinoma,7
358,[Disease]_Lung Carcinoma,1
359,[Disease]_Uterine Corpus Endometrial Carcinoma,7
360,[Variant]_PTEN:EXPRESSION,6
361,[Variant]_NRG1:EXPRESSION,6
362,[Drug]_Seribantumab,0
363,"[Drug]_Cisplatin,Gemcitabine,Carboplatin,Paclitaxel",7
364,[Gene]_AREG,7
365,[Variant]_AREG:EXPRESSION,0
366,[Disease]_Brain Glioma,7
367,[Drug]_Nimotuzumab,4
368,[Gene]_TGFA,6
369,[Variant]_TGFA:EXPRESSION,4
370,[Variant]_EGFR:G724S,7
371,[Gene]_EREG,0
372,[Variant]_EREG:EXPRESSION,1
373,[Gene]_MAPK1,1
374,[Variant]_MAPK1:E322K,7
375,[Variant]_MAPK1:AMPLIFICATION,1
376,[Drug]_WZ4002,7
377,[Variant]_KRAS:A146V,4
378,[Drug]_Abemaciclib,7
379,[Variant]_MET:MUTATION,2
380,[Disease]_Papillary Renal Cell Carcinoma,0
381,[Drug]_Foretinib,7
382,[Drug]_Infigratinib,3
383,"[Drug]_Dovitinib,PD173074",1
384,[Variant]_FGFR3:EXPRESSION,0
385,"[Drug]_Dovitinib,Tyrosine Kinase Inhibitor SU5402,PD173074",7
386,[Gene]_CBLC,5
387,[Variant]_CBLC:EXPRESSION,1
388,[Gene]_PTPRD,7
389,[Variant]_PTPRD:MUTATION,7
390,[Disease]_Head And Neck Carcinoma,7
391,[Drug]_JSI-124,1
392,[Gene]_DEFA1,1
393,[Variant]_DEFA1:EXPRESSION,2
394,[Drug]_Docetaxel,0
395,[Gene]_ERCC1,4
396,[Variant]_ERCC1:EXPRESSION,3
397,[Variant]_NOTCH1:AMPLIFICATION,7
398,[Drug]_NOTCH1 Antibody (PF-06293622),7
399,[Drug]_Patritumab,7
400,[Gene]_WEE1,7
401,[Variant]_WEE1:RS3910384,6
402,"[Drug]_Gemcitabine,Platinum Compound",1
403,[Gene]_FNTB,2
404,[Variant]_FNTB:RS11623866,7
405,[Drug]_Lonafarnib,0
406,[Gene]_PTPRT,0
407,[Variant]_PTPRT:PROMOTER HYPERMETHYLATION,0
408,"[Drug]_JSI-124,Stattic",0
409,[Gene]_VEGFA,6
410,[Variant]_VEGFA:UNDEREXPRESSION,7
411,"[Drug]_Bevacizumab,Fluorouracil,Levoleucovorin,Irinotecan",0
412,[Variant]_DNMT1:EXPRESSION,1
413,[Drug]_Decitabine,4
414,[Variant]_KRAS:MUTATION,7
415,[Gene]_PDCD4,1
416,[Variant]_PDCD4:EXPRESSION,0
417,[Variant]_MGMT:RS16906252,7
418,[Gene]_TFF3,7
419,[Variant]_TFF3:EXPRESSION,1
420,"[Drug]_Aminoglutethimide,Tamoxifen",7
421,[Gene]_DKK1,7
422,[Variant]_DKK1:NUCLEAR EXPRESSION,7
423,"[Drug]_Levoleucovorin,Fluorouracil,Oxaliplatin,Irinotecan",1
424,[Gene]_CD44,7
425,[Variant]_CD44:ISOFORM EXPRESSION,3
426,[Drug]_RG7356,1
427,[Gene]_EGF,0
428,[Variant]_EGF:EXPRESSION,2
429,[Variant]_MDM2:EXPRESSION,7
430,[Disease]_Malignant Pleural Mesothelioma,7
431,"[Drug]_Cisplatin,Pemetrexed",1
432,[Variant]_HMOX1:EXPRESSION,2
433,[Disease]_Leukemia,7
434,"[Drug]_Sunitinib,Sorafenib",7
435,[Disease]_Angiosarcoma,0
436,[Variant]_SPHK1:OVEREXPRESSION,7
437,[Gene]_CASP8,7
438,[Variant]_CASP8:EXPRESSION,7
439,[Disease]_Ewing Sarcoma Of Bone,0
440,[Gene]_EWSR1,4
441,[Gene]_STAG2,7
442,[Drug]_Conatumumab,7
443,[Variant]_TYMS:EXPRESSION,7
444,[Drug]_Pemetrexed,7
445,[Variant]_PBK:OVEREXPRESSION,1
446,[Variant]_SMARCA4:UNDEREXPRESSION,1
447,"[Drug]_Cisplatin,Vinorelbine",6
448,[Gene]_SETBP1,7
449,[Variant]_SETBP1:EXON 4 MUTATION,6
450,[Variant]_SETBP1:G870S,4
451,"[Drug]_Ceritinib,Luminespib,Crizotinib",1
452,[Variant]_ALK:Oncogenic Mutations,7
453,[Drug]_Lorlatinib,0
454,[Variant]_ALK:EML4-ALK C1156Y-L1198F,5
455,"[Drug]_Docetaxel,Cetuximab",1
456,[Disease]_Lung Small Cell Carcinoma,7
457,[Drug]_Chemotherapy,0
458,[Disease]_Stomach Carcinoma,1
459,[Disease]_Esophageal Carcinoma,7
460,[Gene]_CDKN1A,0
461,[Variant]_CDKN1A:EXPRESSION,0
462,[Gene]_ALCAM,7
463,[Variant]_ALCAM:EXPRESSION,7
464,[Gene]_STMN1,0
465,[Variant]_STMN1:EXPRESSION,1
466,[Disease]_Endometrial Carcinoma,7
467,[Gene]_RSF1,2
468,[Variant]_RSF1:AMPLIFICATION,7
469,[Gene]_AR,0
470,[Variant]_AR:OVEREXPRESSION,5
471,[Drug]_Dactolisib,7
472,[Disease]_Head And Neck Cancer,7
473,[Gene]_CDKN1B,2
474,[Variant]_CDKN1B:CYTOPLASMIC MISLOCALIZATION,2
475,[Drug]_Anti-ErbB3 Monoclonal Antibody AV-203,0
476,[Variant]_ERBB3:EXPRESSION,7
477,[Variant]_AR:V7 EXPRESSION,7
478,"[Drug]_Enzalutamide,Abiraterone",0
479,"[Drug]_Lapatinib,Trastuzumab",0
480,[Gene]_CIP2A,7
481,[Gene]_HSPB1,1
482,"[Drug]_Pertuzumab,9F7-F11",6
483,[Gene]_UGT1A,6
484,[Variant]_UGT1A:EXPRESSION,7
485,[Drug]_Ganetespib,7
486,[Variant]_ERBB4:NUCLEAR TRANSLOCATION,7
487,[Variant]_ERBB4:EXPRESSION,1
488,[Gene]_SLFN11,1
489,[Variant]_SLFN11:EXPRESSION,7
490,[Drug]_7-Ethyl-10-Hydroxycamptothecin,7
491,[Gene]_RAC1,4
492,[Variant]_RAC1:P29S,7
493,"[Drug]_Dabrafenib,Vemurafenib",1
494,[Variant]_BIRC5:NUCLEAR EXPRESSION,7
495,"[Drug]_Taxane Compound,Platinum Compound",7
496,[Variant]_TP53:WILD TYPE,7
497,"[Drug]_Capecitabine,Cetuximab,Oxaliplatin",6
498,[Variant]_MRE11:LOSS,7
499,[Drug]_Talazoparib,3
500,"[Drug]_Afatinib,Trastuzumab,Lapatinib",7
501,[Gene]_TOP1,1
502,[Variant]_TOP1:AMPLIFICATION,0
503,[Drug]_Irinotecan,7
504,[Variant]_CDKN1B:EXPRESSION,6
505,[Disease]_Esophageal Cancer,7
506,"[Drug]_Fluorouracil,Cisplatin",7
507,[Gene]_AGR2,0
508,[Variant]_AGR2:EXPRESSION,6
509,"[Drug]_Temsirolimus,Ridaforolimus",7
510,"[Drug]_Ridaforolimus,Temsirolimus",1
511,"[Drug]_Cetuximab,Capecitabine,Oxaliplatin",7
512,[Gene]_NAPRT,7
513,[Variant]_NAPRT:PROMOTER HYPERMETHYLATION,4
514,[Drug]_GNE-617,6
515,[Variant]_EGFR:EXON 18 OVEREXPRESSION,7
516,"[Drug]_Bevacizumab,Erlotinib",0
517,[Gene]_ZEB1,1
518,[Variant]_ZEB1:EXPRESSION,6
519,[Disease]_Mantle Cell Lymphoma,7
520,"[Drug]_Gemcitabine,Cytarabine,Doxorubicin",1
521,"[Drug]_Doxorubicin,Salinomycin",7
522,[Gene]_TIMP1,7
523,[Variant]_TIMP1:OVEREXPRESSION,7
524,[Drug]_Fulvestrant,0
525,[Gene]_PTP4A3,0
526,[Variant]_PTP4A3:OVEREXPRESSION,0
527,[Variant]_TYMS:AMPLIFICATION,7
528,[Gene]_IGF1R,7
529,[Variant]_IGF1R:EXPRESSION,7
530,[Gene]_EPHB4,1
531,[Variant]_EPHB4:EXPRESSION,0
532,[Disease]_Malignant Glioma,7
533,[Drug]_Bevacizumab,7
534,[Disease]_Inflammatory Breast Carcinoma,7
535,[Variant]_TYMS:UNDEREXPRESSION,7
536,[Gene]_TOP2A,1
537,[Variant]_TOP2A:EXPRESSION,7
538,[Variant]_TOP1:EXPRESSION,7
539,"[Drug]_Carboplatin,Topotecan,Cyclophosphamide",0
540,[Gene]_PRKAA2,7
541,[Variant]_PRKAA2:T172 PHOSPHORYLATION,7
542,[Drug]_ACLY SiRNA,7
543,[Gene]_HSPA5,1
544,[Variant]_HSPA5:EXPRESSION,7
545,[Drug]_Anti-EGFR Monoclonal Antibody,7
546,[Disease]_Pancreatic Carcinoma,1
547,[Variant]_EIF4EBP1:PHOSPHORYLATION,7
548,[Variant]_KIT:MUTATION,0
549,[Disease]_Gastrointestinal Stromal Tumor,1
550,"[Drug]_Imatinib,Pictilisib",1
551,[Gene]_TUBB3,7
552,[Variant]_TUBB3:EXPRESSION,7
553,[Drug]_Taxane Compound,7
554,[Variant]_EGFR:Y1092 PHOSPHORYLATION,7
555,"[Drug]_Erlotinib,Gefitinib",7
556,[Variant]_IGF1R:NUCLEAR EXPRESSION,1
557,[Gene]_NTRK2,7
558,[Disease]_Sarcoma,2
559,[Gene]_ASS1,7
560,[Gene]_NTRK1,4
561,[Gene]_RAD23B,7
562,[Drug]_IGF1R Monoclonal Antibody,1
563,[Gene]_CFLAR,4
564,[Variant]_CFLAR:EXPRESSION,7
565,[Gene]_PROM1,7
566,[Variant]_PROM1:EXPRESSION,7
567,[Gene]_FGF19,0
568,[Disease]_Hepatocellular Carcinoma,4
569,[Gene]_KIF23,7
570,[Gene]_NEDD9,7
571,[Gene]_FOXP3,7
572,[Variant]_FOXP3:EXPRESSION,7
573,[Drug]_Epirubicin,7
574,[Drug]_Raltitrexed,7
575,[Variant]_RPS6:PHOSPHORYLATION,5
576,[Variant]_JAK1:OVEREXPRESSION,7
577,[Drug]_Enzastaurin,7
578,"[Drug]_Dactolisib,WYE354,MTOR Kinase Inhibitor PP242",1
579,[Variant]_BRCA1:EXPRESSION,1
580,[Disease]_Malignant Mesothelioma,1
581,[Drug]_Vinorelbine,7
582,[Gene]_DUSP6,0
583,[Variant]_DUSP6:EXPRESSION,7
584,[Variant]_BRAF:MUTATION,7
585,[Variant]_HSPB1:EXPRESSION,7
586,[Disease]_Pancreatic Cancer,7
587,[Drug]_Gemcitabine,1
588,[Disease]_Bile Duct Adenocarcinoma,7
589,[Gene]_NQO1,7
590,[Variant]_NQO1:EXPRESSION,3
591,[Drug]_Amrubicin,7
592,[Variant]_NQO1:P187S,7
593,[Variant]_BRCA1:UNDEREXPRESSION,5
594,"[Drug]_Platinum Compound,Taxane Compound",2
595,"[Drug]_Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",5
596,[Variant]_ABCB1:EXPRESSION,7
597,[Variant]_ALK:ALK FUSIONS,6
598,"[Drug]_Dasatinib,Cetuximab",7
599,[Variant]_CXCR4:EXPRESSION,7
600,[Gene]_MAGEH1,7
601,[Variant]_MAGEH1:EXPRESSION,7
602,[Gene]_ABCC3,1
603,[Variant]_ABCC3:AMPLIFICATION,1
604,"[Drug]_Paclitaxel,Monomethyl Auristatin E",7
605,[Gene]_ABCC10,7
606,[Variant]_ABCC10:EXPRESSION,1
607,[Gene]_ASNS,7
608,[Variant]_ASNS:AMPLIFICATION,7
609,[Drug]_Asparaginase,7
610,[Gene]_CDX2,6
611,[Variant]_CDX2:EXPRESSION,7
612,[Gene]_STAT3,4
613,[Variant]_STAT3:SH2 DOMAIN MUTATION,7
614,[Disease]_T-cell Large Granular Lymphocyte Leukemia,7
615,[Variant]_POU5F1:EXPRESSION,7
616,[Drug]_Oxaliplatin,7
617,[Variant]_ERBB2:KINASE DOMAIN MUTATION,7
618,[Variant]_ERBB2:Y772_A775DUP,5
619,"[Drug]_Afatinib,Sirolimus",7
620,[Variant]_EGFR:C797G,7
621,[Drug]_Osimertinib,7
622,[Variant]_EGFR:C797S,3
623,[Variant]_EGFR:D761Y,7
624,[Variant]_EGFR:T790M,1
625,"[Drug]_Rociletinib,Osimertinib",7
626,[Drug]_Rindopepimut,7
627,[Variant]_ERBB2:SERUM LEVELS,7
628,[Gene]_THBS2,7
629,[Variant]_THBS2:UNDEREXPRESSION,7
630,[Gene]_MMP2,7
631,[Variant]_NTRK1:NTRK1 FUSIONS,7
632,[Variant]_NTRK3:G623R,7
633,[Drug]_Larotrectinib,4
634,[Variant]_NTRK1:G595R,6
635,[Variant]_NTRK1:Fusions,0
636,[Variant]_NTRK3:Fusions,7
637,[Variant]_NTRK2:Fusions,1
638,[Disease]_All Solid Tumors,7
639,[Disease]_B-cell Adult Acute Lymphocytic Leukemia,6
640,[Disease]_Spindle Cell Sarcoma,0
641,[Disease]_Breast Secretory Carcinoma,1
642,[Disease]_Congenital Fibrosarcoma,3
643,[Variant]_IDH1:R132H,7
644,[Drug]_AGI-5198,6
645,[Variant]_TERT:RS2736100,0
646,[Variant]_STAG2:UNDEREXPRESSION,7
647,[Variant]_HLA-DRA:EXPRESSION,7
648,"[Drug]_Nivolumab,Pembrolizumab,Atezolizumab",7
649,[Variant]_MYD88:L265P,7
650,[Disease]_Waldenstroem's Macroglobulinemia,7
651,"[Drug]_Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265",7
652,"[Drug]_B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib",7
653,"[Drug]_Trametinib,Afatinib",7
654,"[Drug]_Afatinib,Trametinib",6
655,[Drug]_MEK Inhibitor RO4987655,7
656,[Variant]_BRAF:WILD TYPE,7
657,"[Drug]_Docetaxel,Selumetinib",2
658,[Drug]_Refametinib,7
659,[Variant]_NRAS:Q61K,7
660,"[Drug]_Everolimus,Binimetinib",3
661,"[Drug]_PI3Kbeta Inhibitor AZD8186,SCH772984",7
662,"[Drug]_Selumetinib,Teprotumumab",5
663,"[Drug]_Selumetinib,Dactolisib",7
664,"[Drug]_Trastuzumab,Lapatinib",7
665,"[Drug]_Afatinib,Trastuzumab",7
666,[Variant]_MRE11:FRAMESHIFT MUTATION,7
667,"[Drug]_Larotrectinib,Lestaurtinib,Crizotinib",7
668,[Variant]_KIT:EXPRESSION,7
669,[Gene]_CBFB,7
670,[Variant]_CBFB:CBFB-MYH11,2
671,[Disease]_Adrenocortical Carcinoma,7
672,[Gene]_KMT2A,7
673,[Variant]_KMT2A:MLL-MLLT3,0
674,[Variant]_HIF1A:3' UTR Polymorphism,4
675,[Variant]_HIF1A:OVEREXPRESSION,7
676,[Variant]_EPAS1:OVEREXPRESSION,7
677,[Variant]_VHL:LOSS,4
678,[Variant]_FLT3:D835,7
679,"[Drug]_Quizartinib,Ponatinib",6
680,"[Drug]_Quizartinib,Sorafenib",7
681,[Gene]_RICTOR,7
682,[Gene]_CHEK1,7
683,[Gene]_MYC,7
684,"[Drug]_Trastuzumab,Irinotecan",6
685,[Drug]_Trastuzumab Emtansine,1
686,[Variant]_PSMB8:NUCLEAR EXPRESSION,0
687,[Variant]_PBK:NUCLEAR EXPRESSION,4
688,[Gene]_PTTG1,7
689,[Variant]_PTTG1:OVEREXPRESSION,7
690,[Gene]_LEPR,3
691,[Disease]_Meningioma,5
692,[Variant]_LEPR:UNDEREXPRESSION,7
693,[Variant]_EGFR:G465R,7
694,[Drug]_Futuximab/Modotuximab Mixture,7
695,[Variant]_NEDD9:EXPRESSION,1
696,[Gene]_ETS2,7
697,[Variant]_ETS2:RS461155,7
698,"[Drug]_Paclitaxel,Cisplatin",1
699,[Gene]_KRT18,6
700,[Variant]_KRT18:UNDEREXPRESSION,7
701,[Gene]_FGF13,2
702,[Variant]_FGF13:CYTOPLASMIC EXPRESSION,3
703,[Gene]_SSX1,7
704,[Variant]_SSX1:SS18-SSX1,1
705,[Gene]_SMARCB1,7
706,[Disease]_Synovial Sarcoma,6
707,[Gene]_SSX4,0
708,[Gene]_SSX2,6
709,[Variant]_SSX2:SS18-SSX2,1
710,[Gene]_PARP1,7
711,[Disease]_Malignant Peripheral Nerve Sheath Tumor,7
712,[Variant]_SSX4:SS18-SSX4,0
713,[Variant]_ABCB1:S893A/T,5
714,"[Drug]_Pertuzumab,Trastuzumab,Docetaxel",7
715,"[Drug]_Panitumumab,Futuximab/Modotuximab Mixture",1
716,[Variant]_EGFR:R451C,4
717,"[Drug]_Panitumumab,Futuximab/Modotuximab Mixture,Cetuximab",0
718,[Variant]_EGFR:K467T,7
719,"[Drug]_Futuximab/Modotuximab Mixture,Panitumumab",7
720,[Gene]_FCGR2A,1
721,[Variant]_FCGR2A:H167R,1
722,[Gene]_FCGR3A,1
723,[Variant]_FCGR3A:F212V,7
724,[Gene]_FCGR2B,7
725,[Variant]_FCGR2B:I232T,7
726,[Variant]_EGFR:P753S,1
727,[Disease]_Skin Squamous Cell Carcinoma,7
728,[Gene]_KMT2C,3
729,"[Drug]_Sirolimus,Cetuximab",0
730,[Disease]_Acute Promyelocytic Leukemia,4
731,"[Drug]_Tretinoin,Arsenic Trioxide",7
732,[Gene]_PML,7
733,[Variant]_PML:B2 DOMAIN MUTATION,2
734,[Variant]_PML:PML-RARA A216V,7
735,[Variant]_PML:PML-RARA L218P,1
736,[Variant]_MET:EXON 14 MUTATION and AMPLIFICATION,7
737,[Drug]_Patidegib,1
738,[Variant]_ROS1:CD74-ROS1 G2032R,1
739,[Gene]_CEBPA,7
740,[Variant]_CEBPA:N-TERMINAL FRAME SHIFT,1
741,[Drug]_OICR-9429,7
742,[Variant]_FGFR1:ZNF198-FGFR1,7
743,[Gene]_PDGFRB,4
744,[Disease]_Myeloproliferative Neoplasm,7
745,[Gene]_CALR,3
746,[Disease]_Systemic Mastocytosis,1
747,[Drug]_Midostaurin,7
748,[Drug]_Afimoxifene,1
749,[Gene]_KDR,7
750,[Variant]_KDR:A1065T,7
751,[Gene]_PTPRB,7
752,[Variant]_KDR:D717V,7
753,[Gene]_TSC2,7
754,[Variant]_TSC2:Q1178*,7
755,[Disease]_Thyroid Gland Carcinoma,1
756,[Variant]_MTOR:F2108L,7
757,[Gene]_RAD51D,2
758,[Variant]_RAD51D:R186*,7
759,"[Drug]_Tretinoin,Anthracycline Antineoplastic Antibiotic",7
760,"[Drug]_Trastuzumab,Neratinib",0
761,[Gene]_ALDH1A2,7
762,[Variant]_ALDH1A2:EXPRESSION,7
763,[Variant]_ALDH1A2:UNDEREXPRESSION,7
764,[Variant]_CIP2A:EXPRESSION,0
765,[Variant]_CIP2A:UNDEREXPRESSION,0
766,[Gene]_MIR218-1,0
767,[Variant]_MIR218-1:EXPRESSION,7
768,[Disease]_Lung Acinar Adenocarcinoma,7
769,[Variant]_BRCA1:P968FS,7
770,[Variant]_BRAF:V600E,1
771,[Disease]_Hairy Cell Leukemia,7
772,[Variant]_KRAS:Q22*,5
773,[Disease]_Colon Mucinous Adenocarcinoma,7
774,"[Drug]_Capecitabine,Lapatinib",7
775,"[Drug]_Capecitabine,Trastuzumab",7
776,[Gene]_DDX43,6
777,[Variant]_DDX43:OVEREXPRESSION,7
778,"[Drug]_Trametinib,Selumetinib,MEK Inhibitor PD0325901",1
779,[Variant]_KIT:RS3733542,2
780,[Gene]_TBK1,7
781,[Variant]_TBK1:OVEREXPRESSION,1
782,"[Drug]_AZ909,Selumetinib",0
783,"[Drug]_Chemotherapy,Bevacizumab",7
784,"[Drug]_MEK Inhibitor GDC-0623,G-573",6
785,[Variant]_ARAF:Oncogenic Mutations,7
786,[Drug]_Cobimetinib,6
787,[Variant]_RAF1:Oncogenic Mutations,7
788,[Variant]_NRAS:Oncogenic Mutations,0
789,[Variant]_KRAS:Oncogenic Mutations,7
790,[Variant]_BRAF:Oncogenic Mutations,7
791,[Disease]_Histiocytosis,1
792,[Variant]_MAP2K2:Oncogenic Mutations,7
793,"[Drug]_Selumetinib,Docetaxel",7
794,[Variant]_STK11:LOSS,7
795,[Drug]_Adjuvant Chemotherapy,7
796,[Gene]_HAVCR2,4
797,[Variant]_HAVCR2:OVEREXPRESSION,1
798,[Drug]_PD1 Inhibitor,7
799,"[Drug]_Anti-TIM-3 Monoclonal Antibody,PD1 Inhibitor",7
800,"[Drug]_Afatinib,Selumetinib",7
801,"[Drug]_Gefitinib,HER2 Inhibitor CP-724,714,Selumetinib",7
802,[Variant]_MMP2:SERUM LEVELS,7
803,[Gene]_MMP9,7
804,[Variant]_MMP9:SERUM LEVELS,5
805,[Gene]_ACTA1,1
806,[Variant]_ACTA1:EXPRESSION,6
807,[Variant]_HSPH1:NUCLEAR EXPRESSION,7
808,"[Drug]_Cisplatin,Fluorouracil",3
809,[Variant]_HSPH1:T17 DELETION,6
810,"[Drug]_Oxaliplatin,Fluorouracil",6
811,[Gene]_ECSCR,7
812,[Variant]_ECSCR:EXPRESSION,7
813,[Drug]_Angiogenesis Inhibitor,7
814,[Gene]_ROBO4,7
815,[Variant]_ROBO4:EXPRESSION,7
816,"[Drug]_Atezolizumab,Avelumab,Pembrolizumab,Nivolumab",7
817,[Gene]_PIM1,7
818,[Variant]_PIM1:NUCLEAR EXPRESSION,1
819,[Variant]_MDM2:SNP309,7
820,[Disease]_Adenosquamous Lung Carcinoma,7
821,[Drug]_Pazopanib,6
822,[Drug]_Atezolizumab,7
823,"[Drug]_Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853",7
824,"[Drug]_Neratinib,Lapatinib,Trastuzumab",6
825,[Variant]_ALK:Fusions,7
826,[Drug]_Ceritinib,7
827,[Disease]_Inflammatory Myofibroblastic Tumor,0
828,[Disease]_Colon Adenocarcinoma,3
829,"[Drug]_Trastuzumab,Lapatinib,Neratinib",7
830,[Variant]_ERBB2:L866M,3
831,"[Drug]_Lapatinib,Neratinib,Trastuzumab",7
832,[Variant]_ERBB2:S310F/Y,0
833,[Drug]_Ixazomib,4
834,[Drug]_AZD5438,1
835,[Variant]_MIR218-1:UNDEREXPRESSION,7
836,[Gene]_RRM2,7
837,[Gene]_RRM1,7
838,[Gene]_FANCC,7
839,[Gene]_PALB2,7
840,[Gene]_SIRT1,7
841,[Drug]_Capmatinib,0
842,[Drug]_WHI-P154,4
843,[Variant]_ALK:EML4-ALK e20-e20,7
844,[Variant]_ALK:EML4-ALK e2-e20,7
845,[Variant]_KDR:R961W,7
846,[Disease]_Colorectal Adenocarcinoma,7
847,[Gene]_JUN,0
848,[Variant]_ALK:EML4-ALK e6-e20,1
849,"[Drug]_2,4-pyrimidinediamine",5
850,[Drug]_Retaspimycin Hydrochloride,7
851,"[Drug]_Retaspimycin Hydrochloride,Crizotinib",1
852,"[Drug]_Alvespimycin,Crizotinib",3
853,[Drug]_Alvespimycin,7
854,[Variant]_TP53:P47S,7
855,[Variant]_GNAQ:MUTATION,7
856,[Disease]_NUT Midline Carcinoma,7
857,[Drug]_JQ1,7
858,[Gene]_GNA11,4
859,[Variant]_GNA11:MUTATION,1
860,[Variant]_GNA11:Q209,7
861,[Variant]_GNAQ:Q209,7
862,[Gene]_PMS2,7
863,[Variant]_PMS2:K706FS*19,1
864,[Drug]_Nivolumab,1
865,[Variant]_Other Biomarkers:Microsatellite Instability-High,1
866,[Drug]_Salirasib,4
867,"[Drug]_Gemcitabine,Erlotinib",7
868,[Variant]_KIT:EXON 9 MUTATION,0
869,"[Drug]_Docetaxel,Trametinib",0
870,[Drug]_Binimetinib,1
871,[Disease]_Ovary Serous Adenocarcinoma,7
872,"[Drug]_Trametinib,Metformin",3
873,[Variant]_PTEN:MUTATION,7
874,"[Drug]_Panobinostat,Valproic Acid,Vorinostat,Trichostatin A",1
875,"[Drug]_Vorinostat,Mocetinostat,MC1568",2
876,[Variant]_FGFR2:MUTATION,7
877,[Variant]_ALK:MUTATION,7
878,[Variant]_ALK:NPM-ALK,1
879,[Disease]_Anaplastic Large Cell Lymphoma,7
880,[Variant]_ALK:RANBP2-ALK,5
881,[Variant]_FGFR1:N546K,7
882,"[Drug]_Foretinib,Cabozantinib",7
883,"[Drug]_AZD3463,Ceritinib,Crizotinib,Brigatinib",7
884,[Variant]_ROS1:CD74-ROS1 L2026M,0
885,[Variant]_ROS1:CD74-ROS1 L2155S,7
886,"[Drug]_Foretinib,TAE684,Crizotinib",7
887,[Variant]_ROS1:CD74-ROS1 G2101A,3
888,[Variant]_ALK:CLTC-ALK,7
889,[Gene]_U2AF1,7
890,[Variant]_U2AF1:MUTATION,7
891,[Gene]_ASXL1,7
892,[Disease]_Myelofibrosis,7
893,[Variant]_BRAF:DEL 485-490,7
894,[Drug]_Pan-RAF Inhibitor LY3009120,6
895,[Gene]_RHOA,7
896,[Gene]_CDH1,1
897,[Gene]_MLH1,6
898,[Gene]_DUX4,7
899,[Variant]_DUX4:DUX4 FUSIONS,2
900,[Variant]_B4GALT1:EXPRESSION,0
901,[Gene]_BCL2L11,7
902,[Variant]_BCL2L11:DELETION POLYMORPHISM,7
903,[Variant]_ALK:ALK FUSION I1171,2
904,[Variant]_ALK:EML4-ALK  V1180L,4
905,[Drug]_Brigatinib,6
906,[Variant]_SIRT1:OVEREXPRESSION,7
907,[Disease]_Pancreatic Ductal Carcinoma,4
908,[Drug]_Niacinamide,7
909,[Variant]_KRAS:G12R,1
910,[Variant]_TP53:P72R,7
911,[Variant]_PALB2:BIALLELIC INACTIVATION,2
912,[Drug]_Mitomycin,7
913,[Variant]_SMAD4:EXPRESSION,1
914,[Variant]_FANCC:LOSS-OF-FUNCTION,7
915,"[Drug]_Mitomycin,Cisplatin,Chlorambucil,Melphalan,Gemcitabine",5
916,[Variant]_PDGFRB:EBF1-PDGFRB,1
917,[Disease]_Malignant Exocrine Pancreas Neoplasm,1
918,[Variant]_RB1:EXPRESSION,6
919,[Variant]_MLH1:METHYLATION,7
920,[Gene]_PTPN11,7
921,[Variant]_PTPN11:EXPRESSION,7
922,[Disease]_Laryngeal Carcinoma,1
923,[Variant]_FLT3:T227M,7
924,[Variant]_PALB2:L531FS*30,7
925,[Variant]_MTOR:S2215Y,7
926,[Disease]_Endometrial Adenocarcinoma,7
927,[Variant]_MTOR:C1483Y,0
928,[Variant]_MTOR:E1799K,1
929,[Variant]_FGFR2:N550K,7
930,[Variant]_RB1:OVEREXPRESSION,7
931,"[Drug]_Gemcitabine,Doxorubicin,Fluorouracil,Mitomycin",7
932,[Gene]_PPP1R15A,7
933,[Variant]_PPP1R15A:RS557806,6
934,"[Drug]_FOLFIRI Regimen,Bevacizumab",7
935,"[Drug]_Irinotecan,Selumetinib",1
936,[Drug]_AZD3463,7
937,[Variant]_ALK:F1245C,1
938,[Variant]_ALK:DEL4-11,7
939,[Variant]_ALK:ALK FUSION F1245C,7
940,[Variant]_ALK:ALK FUSION G1269A,6
941,"[Drug]_Pictilisib,Tanespimycin",7
942,"[Drug]_Tanespimycin,Pictilisib",1
943,"[Drug]_Dactolisib,Cetuximab",5
944,"[Drug]_Pictilisib,Trametinib,Tanespimycin",3
945,[Variant]_CDK4:AMPLIFICATION,7
946,[Disease]_Liposarcoma,7
947,[Variant]_MDM2:Amplification,5
948,[Gene]_DDIT3,1
949,[Variant]_CDKN2A:LOSS,0
950,[Drug]_Alvocidib,7
951,[Variant]_CDKN2B:LOSS,7
952,[Variant]_CDK4:R24C,7
953,[Variant]_ASXL1:EXON 12 MUTATION,7
954,[Drug]_A66,7
955,[Drug]_Tgx 221,2
956,[Variant]_CALR:EXON 9 FRAMESHIFT,7
957,[Gene]_CSF3R,7
958,[Variant]_CSF3R:MUTATION,0
959,[Disease]_Chronic Neutrophilic Leukemia,7
960,[Disease]_Atypical Chronic Myeloid Leukemia,1
961,[Variant]_BRAF:V600K,7
962,"[Drug]_Cetuximab,Gefitinib,Vemurafenib",6
963,[Variant]_SMAD4:LOSS,7
964,"[Drug]_Panitumumab,Vemurafenib",7
965,[Gene]_SF3B1,0
966,[Variant]_SF3B1:K700E,7
967,[Drug]_Spliceostatin A,5
968,[Variant]_SF3B1:K666N,7
969,[Gene]_MAP2K7,7
970,[Variant]_MAP2K7:E116K,7
971,"[Drug]_Cobimetinib,Vemurafenib",7
972,[Disease]_Chronic Leukemia,7
973,[Variant]_PDGFRA:PDGFRA FUSIONS,1
974,[Gene]_ZRSR2,1
975,[Disease]_Chronic Myelomonocytic Leukemia,0
976,[Variant]_ZRSR2:Oncogenic Mutations,7
977,[Variant]_SF3B1:Oncogenic Mutations,3
978,[Variant]_SRSF2:Oncogenic Mutations,7
979,[Gene]_SRSF2,7
980,[Variant]_U2AF1:Oncogenic Mutations,7
981,[Variant]_PDGFRB:PDGFRB FUSIONS,7
982,[Variant]_FGFR1:FGFR1 FUSIONS,7
983,"[Drug]_Dactolisib,GDC-0879",6
984,"[Drug]_Omipalisib,Trametinib",1
985,[Disease]_Gastrointestinal Neuroendocrine Tumor,7
986,"[Drug]_Dabrafenib,Trametinib,Vemurafenib",7
987,"[Disease]_Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1",4
988,[Variant]_JAK2:PCM1-JAK2,7
989,"[Drug]_Pertuzumab,Docetaxel,Trastuzumab",6
990,[Variant]_MTOR:E2014K and E2419K,0
991,[Gene]_MSH6,7
992,[Gene]_MSH2,7
993,[Variant]_RICTOR:AMPLIFICATION,6
994,"[Drug]_Sapanisertib,Onatasertib",2
995,[Variant]_PDGFRA:FIP1L1-PDGFRA,7
996,[Disease]_Bronchiolo-alveolar Adenocarcinoma,7
997,[Variant]_ROS1:TFG-ROS1,2
998,[Variant]_PDGFRA:FIP1L1-PDGFRA T674I,7
999,"[Drug]_Pilaralisib,Trastuzumab",7
1000,[Variant]_BIRC5:OVEREXPRESSION,5
1001,[Variant]_BRAF:D594A,5
1002,"[Drug]_Mitogen-Activated Protein Kinase Kinase Inhibitor,Sorafenib",7
1003,"[Drug]_Trastuzumab,PI3K/BET Inhibitor LY294002",6
1004,[Variant]_BRAF:D594V,4
1005,"[Drug]_Trametinib,Sorafenib",6
1006,[Variant]_BRAF:K483M,1
1007,"[Drug]_Trametinib,Vemurafenib",7
1008,[Variant]_BRAF:L597S,7
1009,"[Drug]_Vemurafenib,Trametinib",7
1010,[Drug]_MEK Inhibitor TAK-733,7
1011,[Variant]_BRAF:L597Q,1
1012,[Variant]_BRAF:K601E,7
1013,[Variant]_BRAF:L597V,5
1014,[Drug]_Taselisib,0
1015,[Variant]_KIT:AMPLIFICATION,1
1016,[Disease]_Mucosal Melanoma,7
1017,[Variant]_NF1:MUTATION,7
1018,"[Drug]_MEK Inhibitor PD0325901,Sirolimus",1
1019,"[Drug]_VTX-11e,AZ628",7
1020,[Drug]_Amuvatinib,7
1021,"[Drug]_Sonidegib,Vismodegib",6
1022,[Disease]_Chronic Lymphocytic Leukemia,1
1023,[Drug]_Alemtuzumab,7
1024,[Drug]_Peginterferon Alfa-2a,7
1025,[Variant]_ALK:HIP1-ALK I1171N,7
1026,"[Drug]_Alectinib,Crizotinib",0
1027,[Variant]_ALK:EML4-ALK I1171S,4
1028,[Gene]_BIRC3,2
1029,[Variant]_BIRC3:TRUNCATING MUTATION,7
1030,"[Drug]_Taselisib,Radiation Therapy",7
1031,[Drug]_Ipatasertib,2
1032,[Disease]_Ovarian Clear Cell Carcinoma,6
1033,[Drug]_GSK126,7
1034,"[Drug]_Paclitaxel,Carboplatin,Sorafenib",7
1035,[Variant]_RAF1:AMPLIFICATION,7
1036,[Variant]_KRAS:AMPLIFICATION,1
1037,"[Drug]_Docetaxel,Carboplatin,Sorafenib",5
1038,"[Drug]_Capivasertib,Docetaxel",7
1039,"[Drug]_Trastuzumab,Capivasertib",7
1040,"[Drug]_Capivasertib,Lapatinib",5
1041,[Variant]_CEBPA:BIALLELIC INACTIVATION,7
1042,[Variant]_SRSF2:MUTATION,7
1043,[Variant]_NRAS:G12/G13,7
1044,[Variant]_RET:OVEREXPRESSION,0
1045,[Disease]_Papillary Adenocarcinoma,7
1046,[Gene]_CTLA4,7
1047,[Variant]_CTLA4:CTLA4-CD28,7
1048,[Disease]_Sezary's Disease,1
1049,[Drug]_Ipilimumab,1
1050,[Variant]_AR:MUTATION,5
1051,"[Drug]_Bicalutamide,Flutamide,Cyproterone Acetate,Nilutamide",1
1052,"[Drug]_Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide",7
1053,[Variant]_NOTCH1:LOSS-OF-FUNCTION,4
1054,[Drug]_Porcupine Inhibitor WNT974,4
1055,[Gene]_CDK6,7
1056,[Variant]_CDK6:OVEREXPRESSION,4
1057,"[Drug]_Palbociclib,Fulvestrant",0
1058,[Variant]_FLT3:OVEREXPRESSION,7
1059,[Gene]_NTRK3,7
1060,[Gene]_CRLF2,0
1061,[Drug]_Platinum Compound,7
1062,[Variant]_GNAQ:Q209P,7
1063,[Variant]_PTEN:V317FS,1
1064,"[Drug]_MEK Inhibitor CI-1040,Akt Inhibitor MK2206",7
1065,[Variant]_RB1:LOSS-OF-FUNCTION,2
1066,[Drug]_PLX4720,1
1067,[Gene]_ESR1,1
1068,[Variant]_ESR1:OVEREXPRESSION,7
1069,[Disease]_Her2-receptor Negative Breast Cancer,0
1070,"[Drug]_Palbociclib,Letrozole",3
1071,[Variant]_MTOR:M2327I,1
1072,[Drug]_MTOR Kinase Inhibitor AZD8055,1
1073,"[Drug]_Sirolimus,RapaLink-1",1
1074,[Variant]_MTOR:A2034V,0
1075,"[Drug]_RapaLink-1,MTOR Kinase Inhibitor AZD8055",3
1076,[Drug]_Apitolisib,7
1077,[Variant]_BRAF:D594G,7
1078,[Variant]_FLT3:D835H,7
1079,[Variant]_FLT3:D835H/Y,7
1080,"[Drug]_Palbociclib,Trastuzumab",7
1081,[Variant]_JAK1:Q503*,7
1082,[Variant]_Other Biomarkers:Tumor Mutational Burden-High,0
1083,[Drug]_Pembrolizumab,7
1084,[Variant]_JAK2:c.1641+1dup,7
1085,[Variant]_B2M:S14FS,7
1086,[Variant]_BRAF:PPFIBP2-BRAF,3
1087,[Variant]_BRAF:KIAA1549-BRAF,7
1088,[Variant]_EGFR:EXPRESSION,4
1089,[Disease]_Langerhans-cell Histiocytosis,4
1090,[Variant]_MET:OVEREXPRESSION,3
1091,"[Drug]_Crizotinib,Vemurafenib",7
1092,[Gene]_POT1,1
1093,[Variant]_POT1:MUTATION,7
1094,[Gene]_MKI67,7
1095,[Variant]_MKI67:EXPRESSION,7
1096,[Disease]_Pseudomyxoma Peritonei,5
1097,[Variant]_RAD23B:EXPRESSION,7
1098,[Drug]_Vorinostat,7
1099,"[Drug]_Cetuximab,Vemurafenib",0
1100,"[Drug]_Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor",7
1101,[Variant]_RET:CCDC6-RET,0
1102,[Drug]_Nintedanib,7
1103,[Variant]_MAP2K1:C121S,7
1104,[Variant]_FGFR3:S249C,0
1105,[Drug]_Dovitinib,1
1106,[Variant]_FGFR2:AMPLIFICATION,7
1107,[Gene]_FGF3,7
1108,[Variant]_FGF3:AMPLIFICATION,1
1109,"[Drug]_Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor",4
1110,[Variant]_VHL:R200W (c.598C>T),1
1111,[Disease]_Chuvash Polycythemia,3
1112,[Variant]_JAK2:PCM1-JAK2 Fusion,4
1113,[Drug]_Ruxolitinib,7
1114,"[Disease]_Chronic Eosinophilic Leukemia, NOS",6
1115,"[Disease]_B-lymphoblastic Leukemia/lymphoma, BCR-ABL1�like",7
1116,[Variant]_RB1:PHOSPHORYLATION,7
1117,"[Drug]_Everolimus,MTOR Kinase Inhibitor PP242",7
1118,[Gene]_PIK3R1,7
1119,[Variant]_PIK3R1:MUTATION,1
1120,[Drug]_MTOR Kinase Inhibitor PP242,7
1121,"[Drug]_Ipilimumab,Nivolumab",7
1122,[Variant]_STK11:D194E,2
1123,[Disease]_Peutz-Jeghers Syndrome,6
1124,"[Drug]_Sirolimus,Everolimus",7
1125,[Variant]_AKT2:AMPLIFICATION,7
1126,"[Drug]_Vandetanib,Everolimus",3
1127,"[Drug]_Fulvestrant,Everolimus",0
1128,[Disease]_Thyroid Gland Cancer,7
1129,"[Drug]_Temsirolimus,Perifosine",7
1130,"[Drug]_Perifosine,Temsirolimus",0
1131,[Variant]_PTEN:R130*,0
1132,[Variant]_FBXW7:LOSS-OF-FUNCTION,7
1133,[Variant]_RB1:M695FS*26,0
1134,[Variant]_JUN:OVEREXPRESSION,6
1135,[Drug]_Irbesartan,7
1136,[Gene]_FOS,7
1137,[Variant]_FOS:OVEREXPRESSION,7
1138,[Variant]_CDKN2A:RS3814960,7
1139,[Variant]_MDM2:RS34886328,7
1140,[Gene]_CBLB,1
1141,[Variant]_CBLB:RS2305035,7
1142,[Gene]_PRDM1,2
1143,[Variant]_PRDM1:MUTATION,1
1144,[Variant]_IDH1:MUTATION,1
1145,"[Drug]_IMG-2005-5,IRAK-1/4 Inhibitor",4
1146,"[Drug]_Refametinib,Sorafenib",7
1147,[Gene]_PRKACA,7
1148,[Disease]_Mixed Fibrolamellar Hepatocellular Carcinoma,6
1149,[Variant]_SMAD4:DELETION,7
1150,[Variant]_LRP1B:DELETION,7
1151,[Gene]_ATRX,7
1152,[Variant]_ATRX:UNDEREXPRESSION,7
1153,[Disease]_Astrocytoma,7
1154,"[Drug]_PCV Regimen,Temozolomide",1
1155,[Variant]_MET:D1228N,2
1156,[Variant]_CASP8:D302H,6
1157,[Variant]_AXL:EXPRESSION,7
1158,[Variant]_GAS6:EXPRESSION,1
1159,[Gene]_ETV4,7
1160,[Variant]_ETV4:OVEREXPRESSION,6
1161,[Gene]_STAG3,1
1162,[Variant]_STAG3:UNDEREXPRESSION,3
1163,[Variant]_MAP2K1:Q56_V60del,1
1164,[Variant]_BRAF:BRAF-CUL1,7
1165,[Drug]_Mitogen-Activated Protein Kinase Kinase Inhibitor,3
1166,[Variant]_BRAF:ZKSCAN1-BRAF,7
1167,"[Drug]_Temsirolimus,Bevacizumab,Sorafenib",7
1168,"[Drug]_Erlotinib,Gefitinib,Afatinib",2
1169,[Variant]_BRAF:L505H,7
1170,"[Drug]_Erlotinib,Afatinib,Gefitinib",3
1171,[Variant]_HIF1A:EXPRESSION,1
1172,"[Drug]_Cediranib,Olaparib",7
1173,[Variant]_BRCA2:D3095E,4
1174,[Variant]_MLH1:EXPRESSION,0
1175,[Gene]_BCOR,2
1176,[Variant]_BCOR:MUTATION,2
1177,[Variant]_CDH1:MUTATION,3
1178,[Variant]_RHOA:MUTATION,1
1179,[Gene]_AKT3,1
1180,[Variant]_ERBB2:MUTATION,7
1181,[Gene]_MEN1,1
1182,[Variant]_MEN1:FRAMESHIFT TRUNCATION,7
1183,[Disease]_Thyroid Gland Hurthle Cell Carcinoma,1
1184,[Variant]_KMT2C:MUTATION,1
1185,[Variant]_STAG2:MUTATION,7
1186,[Variant]_EGFR:MUTATION,7
1187,[Gene]_MYCL,7
1188,[Variant]_MYCL:EXPRESSION,1
1189,[Disease]_Multiple Myeloma,7
1190,"[Drug]_I-BET151,JQ1",7
1191,[Gene]_HGF,7
1192,[Variant]_HGF:EXPRESSION,7
1193,[Drug]_MET Tyrosine Kinase Inhibitor SGX523,7
1194,[Gene]_SOX10,7
1195,[Variant]_SOX10:LOSS,7
1196,[Gene]_FGF2,7
1197,[Variant]_FGF2:EXPRESSION,0
1198,[Variant]_FLT3:Internal tandem duplication,1
1199,[Drug]_Quizartinib,1
1200,[Gene]_EIF1AX,6
1201,[Variant]_EIF1AX:MUTATION,7
1202,[Variant]_PAX8:EXPRESSION,7
1203,[Disease]_Female Reproductive Organ Cancer,7
1204,[Gene]_ERRFI1,7
1205,[Variant]_ERRFI1:E384*,1
1206,[Variant]_ESR1:S463P,3
1207,[Drug]_Aromatase Inhibitor,0
1208,[Gene]_SGK1,7
1209,[Variant]_SGK1:OVEREXPRESSION,7
1210,"[Drug]_Alpelisib,SGK1-Inh",1
1211,[Drug]_CDK Inhibitor SNS-032,7
1212,[Disease]_Ovarian Serous Cystadenocarcinoma,7
1213,"[Drug]_Dinaciclib,Akt Inhibitor MK2206",7
1214,[Variant]_BRAF:G596C,3
1215,[Disease]_Thyroid Gland Anaplastic Carcinoma,3
1216,"[Drug]_Trametinib,Dabrafenib",1
1217,[Variant]_SMARCB1:UNDEREXPRESSION,0
1218,[Variant]_SMARCB1:Oncogenic Mutations,7
1219,[Drug]_Tazemetostat,7
1220,[Disease]_All Liquid Tumors,5
1221,[Variant]_KDM6A:Oncogenic Mutations,1
1222,[Disease]_Follicular Lymphoma,7
1223,"[Variant]_EZH2:A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S",6
1224,[Disease]_Epithelioid Sarcoma,7
1225,[Variant]_SMARCB1:Deletion,0
1226,[Disease]_Rhabdoid Cancer,7
1227,[Variant]_SMARCB1:DELETION,7
1228,[Variant]_NF2:LOSS,7
1229,[Variant]_NF1:LOSS,7
1230,[Drug]_JQ1 Compound,1
1231,[Gene]_SH2B3,7
1232,[Variant]_SH2B3:RS3184504,0
1233,[Variant]_KIF23:EXPRESSION,7
1234,[Variant]_ERBB3:V104M,7
1235,[Variant]_ERBB3:R103G,7
1236,[Variant]_ERBB3:G284R,7
1237,[Gene]_GADD45A,2
1238,[Variant]_GADD45A:rs681673,7
1239,[Variant]_EWSR1:EWSR1-FLI1,7
1240,[Variant]_BRCA2:TRUNCATING MUTATION,1
1241,[Variant]_BRCA1:Alu insertion,2
1242,[Gene]_HOXB13,7
1243,[Variant]_HOXB13:G84E,7
1244,[Variant]_KLLN:PROMOTER METHYLATION,7
1245,[Gene]_CRBN,7
1246,[Variant]_CRBN:MUTATION,7
1247,"[Drug]_Lenalidomide,Pomalidomide",0
1248,[Gene]_TSC1,1
1249,[Variant]_TSC1:R1062W,5
1250,[Disease]_Tuberous Sclerosis,0
1251,[Variant]_STK11:MUTATION,7
1252,[Variant]_PDGFRA:AMPLIFICATION,7
1253,[Variant]_DDIT3:EWSR1-DDIT3,7
1254,[Disease]_Myxoid Liposarcoma,1
1255,[Gene]_BRD4,6
1256,[Variant]_BRD4:BRD4-NUTM1,7
1257,[Variant]_EGFR:S720,7
1258,[Gene]_CYP2D6,7
1259,[Variant]_CYP2D6:LOSS-OF-FUNCTION,7
1260,[Variant]_DDIT3:FUS-DDIT3,7
1261,[Variant]_EGFR:K757R,1
1262,[Variant]_EGFR:E746G,7
1263,[Variant]_MLH1:E13FS*3,0
1264,[Gene]_EPCAM,7
1265,[Disease]_Lynch Syndrome,1
1266,[Variant]_MSH2:R383*,7
1267,[Variant]_MLH1:V534R,7
1268,[Gene]_UGT1A1,7
1269,[Variant]_UGT1A1:UGT1A1*28,6
1270,[Drug]_Belinostat,0
1271,[Variant]_MLH1:G606FS*2,7
1272,[Variant]_MLH1:c.790+1G>A,7
1273,[Variant]_UGT1A1:UGT1A1*60,6
1274,[Variant]_MLH1:K618DEL,7
1275,[Variant]_MLH1:R687FS,7
1276,[Variant]_EGFR:V769_770insASV,7
1277,[Gene]_DPYD,0
1278,[Variant]_DPYD:DPYD*2A HOMOZYGOSITY,7
1279,"[Drug]_Capecitabine,Fluorouracil,Tegafur",0
1280,[Variant]_DPYD:DPYD*13 HOMOZYGOSITY,0
1281,"[Drug]_Tegafur,Fluorouracil,Capecitabine",1
1282,[Variant]_FOS:TRUNCATING FUSION,1
1283,[Disease]_Bone Epithelioid Hemangioma,3
1284,[Variant]_DPYD:RS67376798 HOMOZYGOSITY,7
1285,"[Drug]_Tegafur,Capecitabine,Fluorouracil",7
1286,[Variant]_MLH1:R100*,7
1287,[Gene]_WWTR1,7
1288,[Variant]_WWTR1:WWTR1-CAMTA1,7
1289,[Disease]_Malignant Epithelioid Hemangioendothelioma,7
1290,[Variant]_MLH1:T117M,4
1291,[Variant]_MLH1:Q426FS,7
1292,[Variant]_MLH1:V49A,1
1293,[Variant]_EGFR:EXON 20 INSERTION,1
1294,[Variant]_MLH1:D667FS,0
1295,[Variant]_MLH1:M1L,7
1296,[Variant]_MLH1:*757L,7
1297,[Variant]_MLH1:R265G,0
1298,[Variant]_MLH1:V213FS,7
1299,[Variant]_MLH1:N551T,1
1300,[Variant]_MLH1:A424T,4
1301,[Variant]_MLH1:Q149*,1
1302,[Variant]_MLH1:R226*,0
1303,[Variant]_MLH1:P536FS,7
1304,[Variant]_MLH1:G67R,7
1305,[Variant]_MLH1:I68S,2
1306,[Variant]_MLH1:G65D,7
1307,[Variant]_MLH1:A681V,7
1308,[Variant]_MSH6:P138T,0
1309,[Variant]_MSH2:V273FS,1
1310,[Variant]_MSH2:E28FS,7
1311,[Variant]_VHL:E55FS (c.163_164delGA),7
1312,[Disease]_Von Hippel-Lindau Disease,7
1313,[Variant]_MSH6:I891FS,1
1314,[Variant]_VHL:E55RfsTer11 (c.163delG),7
1315,[Variant]_MSH6:R1242H,1
1316,[Variant]_MLH1:M490T,7
1317,[Variant]_MSH2:K172*,7
1318,[Variant]_VHL:A56FS (c.164_165insG),1
1319,[Variant]_MSH2:E483G,7
1320,[Variant]_PDGFRA:TNKS2-PDGFRA,7
1321,[Variant]_MSH6:V352I,1
1322,[Variant]_MSH6:R1242C,7
1323,[Gene]_SLCO1B1,7
1324,[Variant]_SLCO1B1:RS4149056,0
1325,[Drug]_Methotrexate,7
1326,[Variant]_SLCO1B1:N130D,6
1327,[Variant]_TYMS:RS34743033,7
1328,[Gene]_GLI1,7
1329,[Variant]_GLI1:ACTB-GLI1,7
1330,[Disease]_Pericytoma,7
1331,[Variant]_ERBB3:V855A,7
1332,"[Drug]_Pertuzumab,Afatinib",7
1333,[Variant]_FGFR2:FGFR2-BICC1,7
1334,[Variant]_FGFR2:FGFR2-AHCYL1,0
1335,[Variant]_CDKN2B:METHYLATION,7
1336,[Variant]_CHEK2:1100DELC,7
1337,"[Drug]_PD173074,Infigratinib",6
1338,[Variant]_CHEK2:I157T,7
1339,[Variant]_CHEK2:IVS2+1G>A,2
1340,[Variant]_PTPRD:V253I,7
1341,"[Drug]_Teprotumumab,Cixutumumab",1
1342,[Variant]_VHL:A56fs (c.164_165insA),7
1343,[Variant]_VHL:E55= (c.165G>A),1
1344,[Variant]_RRM1:OVEREXPRESSION,7
1345,[Variant]_RRM2:OVEREXPRESSION,7
1346,[Variant]_POLE:MUTATION,0
1347,[Variant]_MET:D1228V,7
1348,[Drug]_Savolitinib,7
1349,[Variant]_RB1:MUTATION,7
1350,[Variant]_NTRK1:SQSTM1-NTRK1,7
1351,[Drug]_Entrectinib,7
1352,[Variant]_ROS1:Fusions,7
1353,[Disease]_Salivary Gland Carcinoma,5
1354,[Variant]_NTRK3:ETV6-NTRK3,7
1355,[Gene]_RUNX1,7
1356,[Variant]_RUNX1:K83E,7
1357,[Variant]_RUNX1:Y260*,6
1358,[Variant]_RUNX1:R135FSX177,7
1359,[Variant]_NTRK3:ETV6-NTRK3 G623R,7
1360,[Variant]_RUNX1:D198Y,7
1361,[Variant]_RUNX1:A107P,7
1362,[Variant]_MSH2:LOSS,7
1363,"[Drug]_Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab",2
1364,[Variant]_MSH6:LOSS,7
1365,[Disease]_Ewing Sarcoma,1
1366,"[Drug]_Palbociclib,Linsitinib",7
1367,[Variant]_PDGFB:COL1A1-PDGFB Fusion,1
1368,[Disease]_Dermatofibrosarcoma Protuberans,7
1369,[Gene]_PDGFB,1
1370,[Variant]_RUNX1:T148HFSX9,7
1371,[Gene]_DDX41,0
1372,[Variant]_DDX41:R164W,7
1373,[Variant]_ERBB2:G776L,7
1374,[Variant]_ERBB2:G778_P780DUP,7
1375,[Variant]_ERBB2:M774DELINSWLV,7
1376,[Variant]_PTPRB:LOSS-OF-FUNCTION,6
1377,[Variant]_VHL:A149S (c.445G>T),2
1378,[Drug]_Rucaparib,7
1379,"[Disease]_Prostate Cancer, NOS",4
1380,[Disease]_Peritoneal Serous Carcinoma,2
1381,[Drug]_Therapeutic Tumor Infiltrating Lymphocytes,7
1382,[Gene]_HLA-C,4
1383,[Variant]_HLA-C:COPY-NEUTRAL LOSS OF HETEROZYGOSITY,7
1384,[Variant]_JAK1:S703I,7
1385,[Variant]_EPCAM:3' EXON DELETION,7
1386,"[Drug]_Vemurafenib,Irinotecan,Cetuximab",1
1387,[Gene]_ARAF,7
1388,[Variant]_ARAF:S490T,2
1389,"[Drug]_Irinotecan,Vemurafenib,Cetuximab",7
1390,[Variant]_GNAS:R201C,7
1391,"[Drug]_Cetuximab,Vemurafenib,Irinotecan",7
1392,[Variant]_FGFR3:MUTATION,7
1393,[Variant]_FGFR2:FGFR2 fusions,7
1394,[Variant]_VHL:M54IFS (c.162_166delGGAGG),7
1395,[Variant]_FGFR2:Fusions,7
1396,[Drug]_Erdafitinib,7
1397,"[Variant]_FGFR3:G370C, R248C, S249C, Y373C",7
1398,[Variant]_FGFR3:Fusions,7
1399,[Disease]_Adrenal Carcinoma,7
1400,[Variant]_FGFR3:FGFR3-TACC3,7
1401,[Variant]_AKT3:OVEREXPRESSION,7
1402,[Drug]_Pan-AKT Kinase Inhibitor GSK690693,7
1403,"[Drug]_Pol I Inhibitor CX5461,Quarfloxin",1
1404,[Variant]_PTEN:R173C,7
1405,[Disease]_Endometrial Hyperplasia,0
1406,[Disease]_PTEN Hamartoma Tumor Syndrome,1
1407,[Variant]_ALK:ALTERNATIVE TRANSCRIPT (ATI),7
1408,[Variant]_VHL:EXON 1-3 DELETION,4
1409,[Variant]_VHL:EXON 1 DELETION,7
1410,[Variant]_VHL:EXON 1-2 DELETION,7
1411,[Variant]_VHL:M1FS (c.1_17del17),7
1412,[Variant]_VHL:M1? (c.1-1_20del21),7
1413,[Variant]_VHL:M1? (c.3G>A),7
1414,[Variant]_VHL:N7D (c.19A>G),1
1415,[Variant]_VHL:P25L (c.74C>T),2
1416,[Variant]_VHL:P59fs (c.173_174insC),7
1417,[Variant]_VHL:Y98FS (c.291_310del20),7
1418,"[Drug]_Sotrastaurin Acetate,MEK Inhibitor PD0325901",7
1419,[Disease]_Plexiform Neurofibroma,7
1420,[Variant]_NTRK1:EXPRESSION,0
1421,[Variant]_PDGFRA:P577S,7
1422,"[Drug]_Crenolanib,Imatinib",7
1423,[Variant]_PDGFRA:R841K,0
1424,"[Drug]_Imatinib,Crenolanib",7
1425,[Variant]_PDGFRA:H845Y,7
1426,[Variant]_PDGFRA:G853D,7
1427,"[Drug]_Cetuximab,Crizotinib",7
1428,[Gene]_MTAP,7
1429,[Variant]_MTAP:Underexpression,7
1430,[Drug]_Pyrimidine Antagonist,7
1431,[Gene]_VPS37A,7
1432,[Variant]_VPS37A:UNDEREXPRESSION,0
1433,[Disease]_Chordoma,7
1434,[Gene]_BTK,7
1435,[Variant]_BTK:T316A,7
1436,[Variant]_ERBB2:T862A,7
1437,[Variant]_ERBB2:V773A,7
1438,[Variant]_ERBB2:N857S,7
1439,[Variant]_ERBB2:H878Y,7
1440,[Drug]_FGFR Inhibitor AZD4547,7
1441,[Variant]_ERBB2:OVEREXPRESSION,7
1442,[Variant]_GNAS:R201,7
1443,[Variant]_GNAS:c.393T>C,0
1444,[Disease]_Intrahepatic Cholangiocarcinoma,7
1445,[Disease]_Breast Carcinoma,7
1446,[Variant]_PIK3CA:C420R,7
1447,[Variant]_NRAS:G12D,7
1448,"[Drug]_Cetuximab,Irinotecan",1
1449,[Drug]_Melphalan,7
1450,"[Drug]_Bevacizumab,Sunitinib",7
1451,[Drug]_Pictilisib Bismesylate,7
1452,[Variant]_PIK3CA:WILD TYPE,4
1453,[Drug]_Aspirin,6
1454,[Drug]_PI103,7
1455,[Variant]_PIK3CA:RARE MUTATION,7
1456,"[Drug]_Oxaliplatin,Bevacizumab,Capecitabine",7
1457,[Variant]_EGFR:Ex19 del L858R,0
1458,[Drug]_Canertinib,4
1459,[Variant]_ABL1:BCR-ABL F359V,7
1460,[Variant]_ABL1:BCR-ABL1 Fusion,7
1461,[Drug]_Nilotinib,1
1462,[Disease]_Chronic Myelogenous Leukemia,7
1463,[Disease]_B-Lymphoblastic Leukemia/Lymphoma,4
1464,"[Variant]_ABL1:F317C, F317I, F317L, F317V, T315A, V299L",7
1465,[Disease]_Chronic Myeloid Leukemia,7
1466,"[Drug]_Cetuximab,Chemotherapy",7
1467,[Variant]_PIK3CA:Q546K,7
1468,"[Drug]_Irinotecan,Cetuximab",7
1469,[Variant]_NRAS:G13R,7
1470,[Variant]_KRAS:A146T,3
1471,[Variant]_PIK3CA:E545Q,0
1472,[Variant]_ATM:T2666A,7
1473,[Variant]_ATM:R3008C,7
1474,[Variant]_ATM:c.902-1G>T,0
1475,[Variant]_KRAS:A146P,7
1476,[Variant]_KRAS:G12S,7
1477,[Variant]_TP53:R273L,7
1478,"[Drug]_Etoposide,Cisplatin,Mitomycin",7
1479,[Variant]_TP53:Y220C,0
1480,"[Drug]_Cisplatin,Etoposide,Mitomycin",7
1481,[Drug]_EAP Protocol,7
1482,[Variant]_IDH1:Oncogenic Mutations,0
1483,[Drug]_Ivosidenib,7
1484,[Drug]_BPTES,3
1485,[Variant]_KIT:T417_D419delinsY,7
1486,[Variant]_KIT:F506_F508DUP,1
1487,[Variant]_KIT:N822H,7
1488,[Variant]_KIT:N822K,7
1489,[Variant]_PDGFRA:V561D,7
1490,[Variant]_PDGFRA:D842_H845DELDIMH,7
1491,[Variant]_KIT:K484_G487DEL,7
1492,[Variant]_KIT:V560G,7
1493,[Variant]_KIT:K642E,7
1494,[Variant]_KIT:EXON 13 MUTATION,7
1495,[Variant]_KIT:W557_K558DELWK,2
1496,[Variant]_KIT:Y503_F504insAY,7
1497,[Variant]_PDGFRA:EXON 18 MUTATION,7
1498,[Variant]_KIT:D579DEL,4
1499,[Variant]_EGFR:G719A,7
1500,[Variant]_EGFR:WILDTYPE,1
1501,[Variant]_EGFR:E746_A750del,7
1502,[Variant]_ABL1:BCR-ABL M244V,4
1503,[Variant]_ABL1:BCR-ABL L248V,6
1504,"[Drug]_Nilotinib,Imatinib Mesylate,Dasatinib",7
1505,[Variant]_ABL1:BCR-ABL G250E,7
1506,[Variant]_ABL1:BCR-ABL Q252H,7
1507,[Variant]_ABL1:BCR-ABL Y253H,1
1508,"[Drug]_Nilotinib,Imatinib Mesylate",7
1509,[Variant]_ABL1:Y253F,7
1510,[Variant]_ABL1:BCR-ABL E255V,6
1511,[Variant]_ABL1:BCR-ABL D276G,7
1512,[Variant]_ABL1:BCR-ABL E355G,0
1513,"[Drug]_Bafetinib,Nilotinib",4
1514,[Variant]_ABL1:S417Y,7
1515,[Variant]_ABL1:BCR-ABL M351T,7
1516,[Variant]_ABL1:BCR-ABL H396R,7
1517,[Variant]_TP53:OVEREXPRESSION,6
1518,[Variant]_TP53:Y234C,7
1519,[Variant]_TP53:ALTERATION,7
1520,"[Drug]_Mitomycin,Cisplatin,Etoposide",7
1521,[Variant]_TP53:R282L,7
1522,[Variant]_TP53:R213P,7
1523,"[Drug]_Cisplatin,Etoposide,Doxorubicin",7
1524,[Variant]_ABL1:BCR-ABL F486S,7
1525,[Variant]_ATM:c.7089+1del,7
1526,[Variant]_ATM:c.7515+1_2del,7
1527,[Variant]_ATM:K293*,7
1528,[Variant]_ATM:F1025L,4
1529,[Variant]_ATM:D1930V,7
1530,[Variant]_ATM:E2187*,7
1531,[Variant]_ATM:L2427P,7
1532,[Variant]_ATM:F2732V,7
1533,[Variant]_ATM:K468FS,7
1534,[Variant]_ATM:D1682H,7
1535,[Variant]_ATM:A2062V,7
1536,[Variant]_ATM:C2488Y,0
1537,"[Drug]_Imatinib Mesylate,Nilotinib",7
1538,[Variant]_ABL1:BCR-ABL E292V,7
1539,[Variant]_ABL1:BCR-ABL F359C,7
1540,[Variant]_ABL1:BCR-ABL L384M,7
1541,[Variant]_ABL1:BCR-ABL V299L,7
1542,[Variant]_ABL1:BCR-ABL L387F,7
1543,[Variant]_ABL1:BCR-ABL G398R,7
1544,[Variant]_PIK3CA:K111N,7
1545,[Variant]_PIK3CA:I391M,7
1546,[Variant]_BRCA1:Q1467*,3
1547,[Variant]_BRCA2:M1R,7
1548,[Variant]_BRCA2:M1I,7
1549,[Variant]_BRCA2:V159M,7
1550,[Variant]_BRCA2:V211L,7
1551,[Variant]_BRCA2:V211I,7
1552,[Variant]_BRCA2:R2336P,7
1553,[Variant]_KIT:D820Y,7
1554,[Disease]_Bladder Urothelial Carcinoma,7
1555,[Variant]_MGMT:UNDEREXPRESSION,7
1556,[Disease]_Neuroendocrine Tumor,3
1557,[Variant]_RRM1:UNDEREXPRESSION,4
1558,[Disease]_Urinary Bladder Cancer,7
1559,"[Drug]_Cisplatin,Gemcitabine",6
1560,"[Drug]_Trametinib,Selumetinib",7
1561,[Variant]_RET:C609Y,7
1562,"[Drug]_FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,Infigratinib,FGFR Inhibitor AZD4547",7
1563,[Variant]_KIT:Y823D,7
1564,[Variant]_KIT:C809G,7
1565,[Variant]_KIT:D820A,7
1566,[Variant]_KIT:D820G,7
1567,[Variant]_KIT:D816H,7
1568,[Variant]_KIT:T670I,7
1569,"[Drug]_Nivolumab,Atezolizumab,Pembrolizumab",7
1570,[Variant]_BRAF:AMPLIFICATION,7
1571,"[Drug]_Panitumumab,Dabrafenib",1
1572,"[Drug]_Binimetinib,Ribociclib",7
1573,[Variant]_ROS1:G2032R,1
1574,[Variant]_MAP2K1:K57N,7
1575,[Gene]_CTAG1B,7
1576,[Variant]_CTAG1B:OVEREXPRESSION,7
1577,[Drug]_Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced C259 T Lymphocytes GSK3377794,7
1578,[Gene]_CTAG2,7
1579,[Variant]_CTAG2:OVEREXPRESSION,1
1580,[Variant]_NTRK3:NTRK3 FUSIONS,7
1581,[Variant]_NTRK1:LMNA-NTRK1 e2-e11,4
1582,[Variant]_NTRK1:AMPLIFICATION,3
1583,[Variant]_NTRK3:AMPLIFICATION,7
1584,[Variant]_NTRK1:LMNA-NTRK1 e11-e10,7
1585,[Variant]_NTRK1:LMNA-NTRK1 G595R and G667C,7
1586,[Drug]_Nutlin-3a,7
1587,[Drug]_AMGMDS3,7
1588,[Drug]_RG7112,7
1589,[Gene]_DCC,7
1590,[Variant]_DCC:EXPRESSION,7
1591,[Variant]_CTNNB1:T41A,1
1592,[Disease]_Desmoid Tumor,7
1593,[Variant]_CTNNB1:S45F,7
1594,[Variant]_CTNNB1:S45P,7
1595,[Gene]_ARID1A,7
1596,[Variant]_ARID1A:LOSS-OF-FUNCTION,7
1597,[Variant]_ALK:F1245V,7
1598,[Variant]_CTNNB1:ACTIVATING MUTATION,7
1599,"[Drug]_Anti-PD-L1 Monoclonal Antibody,Anti-CTLA-4 Monoclonal Antibody",1
1600,[Gene]_MERTK,0
1601,[Variant]_MERTK:OVEREXPRESSION,7
1602,[Drug]_UNC1062,7
1603,[Variant]_TP53:CONSERVED DOMAIN MUT,1
1604,[Drug]_Radiation Therapy,7
1605,[Variant]_MYC:OVEREXPRESSION,0
1606,"[Drug]_Olaparib,Prexasertib,Cisplatin",7
1607,[Variant]_FLT3:D835V,7
1608,[Drug]_Tandutinib,7
1609,"[Drug]_Cytarabine,Sunitinib",7
1610,"[Drug]_Sunitinib,Daunorubicin",7
1611,"[Drug]_Osimertinib,Rociletinib",7
1612,[Variant]_KIT:V559D,1
1613,"[Drug]_Dasatinib,Sunitinib,PD-180970,Tandutinib,Imatinib",7
1614,"[Drug]_Tyrphostin AG 1296,AS602868",6
1615,[Variant]_GNAS:R201H,6
1616,[Drug]_Radioactive Iodine,7
1617,[Variant]_BRAF:Non-V600,0
1618,[Variant]_NRAS:Q61H,1
1619,"[Drug]_Teprotumumab,Erlotinib",7
1620,[Variant]_PIK3CA:E545G,6
1621,"[Drug]_Cetuximab,FOLFOX-4 Regimen",7
1622,[Disease]_Childhood Pilocytic Astrocytoma,7
1623,"[Drug]_Erlotinib,Multikinase Inhibitor AEE788,Gefitinib",7
1624,"[Drug]_Multikinase Inhibitor AEE788,Gefitinib,Erlotinib",7
1625,[Drug]_Bosutinib,7
1626,"[Variant]_ABL1:E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, T315A, Y253H",7
1627,[Drug]_Axitinib,1
1628,[Variant]_PIK3CA:R88Q,7
1629,[Variant]_NRAS:G12C,7
1630,[Variant]_PIK3CA:G1049R,7
1631,[Variant]_KRAS:Q61H,7
1632,[Variant]_KRAS:Q61L,7
1633,[Variant]_KRAS:Q61R,6
1634,[Variant]_KRAS:Q61K,7
1635,[Variant]_KRAS:A146,2
1636,[Variant]_PIK3CA:N345K,7
1637,[Variant]_KIT:V560_L576DEL,5
1638,[Variant]_KIT:K550_K558del,7
1639,[Variant]_KIT:V560D,7
1640,"[Drug]_Imatinib,Ponatinib",7
1641,"[Drug]_Regorafenib,Sunitinib",2
1642,[Variant]_KIT:K558_V559del,7
1643,[Variant]_KIT:A502_Y503insAY,0
1644,[Variant]_BRAF:EXON 15 MUTATION,7
1645,[Variant]_KIT:P551_E554delPMYE,3
1646,"[Drug]_Regorafenib,Imatinib,Ponatinib,Sunitinib",7
1647,"[Drug]_Imatinib,Dasatinib",7
1648,[Variant]_KIT:WILDTYPE,7
1649,[Variant]_EGFR:R108K,7
1650,[Variant]_EGFR:T263P,7
1651,[Variant]_EGFR:A289V,7
1652,[Variant]_EGFR:V742A,1
1653,[Variant]_EGFR:E746_T751>I,7
1654,[Variant]_EGFR:G719D,7
1655,[Variant]_EGFR:V774A,7
1656,[Variant]_EGFR:V774M,7
1657,[Variant]_EGFR:K806E,7
1658,[Variant]_EGFR:N826Y,3
1659,[Variant]_EGFR:V834I,1
1660,[Variant]_EGFR:L838P,7
1661,[Variant]_EGFR:N842S,7
1662,[Variant]_EGFR:T847I,1
1663,[Variant]_EGFR:V851I,7
1664,[Variant]_EGFR:L747_P753delinsS,3
1665,[Variant]_EGFR:D770_N771insSVD,7
1666,[Variant]_EGFR:H773_V774insH,7
1667,[Variant]_EGFR:R831H,7
1668,[Variant]_EGFR:L838V,7
1669,[Variant]_EGFR:L861,7
1670,[Variant]_EGFR:E868G,4
1671,[Variant]_ABL1:BCR-ABL L387M,7
1672,[Variant]_PIK3CA:H1047L,7
1673,[Variant]_ABL1:BCR-ABL L364I,7
1674,"[Drug]_Imatinib,Regorafenib,Sunitinib",2
1675,"[Drug]_Ponatinib,Regorafenib,Imatinib",7
1676,[Variant]_PIK3CA:S158L,0
1677,[Variant]_PIK3CA:E81K,7
1678,"[Drug]_Cetuximab,Oxaliplatin,Fluorouracil",0
1679,[Variant]_PIK3CA:R93W,7
1680,[Variant]_EGFR:R776C,2
1681,[Variant]_ABL1:L298V,7
1682,[Variant]_ABL1:BCR-ABL F311I,7
1683,[Variant]_ABL1:BCR-ABL E453Q,7
1684,[Variant]_ARID1A:Q456*,7
1685,[Variant]_EGFR:H773_V774insNPH,7
1686,[Variant]_EGFR:D770_N771insGL,2
1687,[Variant]_EGFR:A864T,7
1688,[Variant]_EGFR:N826S,7
1689,[Variant]_AKT3:E17K,7
1690,[Variant]_ABL1:BCR-ABL F359I,1
1691,[Variant]_ABL1:BCR-ABL M343T,7
1692,[Variant]_ABL1:BCR-ABL F317V,7
1693,[Variant]_ABL1:BCR-ABL E279K,7
1694,[Variant]_ABL1:BCR-ABL Q300R,7
1695,[Variant]_ABL1:BCR-ABL F311L,7
1696,[Variant]_ABL1:BCR-ABL N331S,7
1697,[Variant]_ABL1:BCR-ABL L364P,7
1698,[Variant]_ABL1:BCR-ABL H396P,7
1699,[Variant]_ABL1:BCR-ABL D421G,2
1700,[Variant]_ABL1:BCR-ABL E450V,7
1701,[Variant]_ABL1:BCR-ABL E453K,7
1702,[Variant]_ABL1:BCR-ABL E453A,7
1703,[Variant]_ABL1:BCR-ABL P480A,7
1704,[Variant]_KIT:K550_W557del,7
1705,"[Drug]_Imatinib,Ponatinib,Sunitinib,Regorafenib",7
1706,[Variant]_KIT:K558NP,1
1707,"[Drug]_Imatinib,Regorafenib,Ponatinib,Sunitinib",1
1708,[Variant]_KIT:V569_L576DEL,0
1709,[Variant]_BRCA1:W1815X,7
1710,[Disease]_Endometrioid Ovary Carcinoma,7
1711,"[Drug]_Regorafenib,Imatinib,Ponatinib",7
1712,[Variant]_KIT:D816E,7
1713,"[Drug]_Imatinib,Sunitinib",7
1714,[Variant]_EGFR:D770_N771insGT,7
1715,[Variant]_SMO:L412F,7
1716,[Variant]_EGFR:W731L,7
1717,[Variant]_EGFR:E734Q,3
1718,[Variant]_EGFR:T785A,7
1719,[Variant]_EGFR:C797Y,7
1720,[Variant]_EGFR:Y801H,7
1721,[Variant]_EGFR:A767_V769dupASV,7
1722,[Variant]_EGFR:L747_S752delinsQ,7
1723,[Variant]_EGFR:L861R,7
1724,[Variant]_ABL1:BCR-ABL D363G,7
1725,[Variant]_ABL1:BCR-ABL V379I,7
1726,[Variant]_ABL1:BCR-ABL A397P,7
1727,[Variant]_ABL1:BCR-ABL E98G,7
1728,[Variant]_BRAF:G596R,1
1729,[Variant]_EGFR:RARE Exon 18-21 Mutation,7
1730,[Variant]_ABL1:C475V,7
1731,[Variant]_ABL1:BCR-ABL N336S,7
1732,[Gene]_POLD1,7
1733,[Variant]_POLD1:C284Y,0
1734,[Variant]_POLD1:E374K,7
1735,[Gene]_PIK3R2,7
1736,[Variant]_PIK3R2:N561D,1
1737,[Variant]_PIK3CA:D350G,7
1738,[Variant]_NRAS:Q179X,7
1739,[Variant]_ABL1:R351W,0
1740,[Variant]_ABL1:G340L,6
1741,"[Drug]_Imatinib Mesylate,Dasatinib",7
1742,[Variant]_KIT:S628N,7
1743,[Variant]_EGFR:M766_A767insAI,3
1744,[Variant]_EGFR:Y764_V765insHH,7
1745,[Variant]_EGFR:D770_N771insGY,7
1746,[Variant]_EGFR:P772_H773insYNP,7
1747,[Variant]_EGFR:P772_V774insPHV,7
1748,[Variant]_JAK2:F547 SPLICE SITE MUTATION,6
1749,[Variant]_ARID1A:P1175FS*5,7
1750,[Drug]_Anti-VEGF Monoclonal Antibody,7
1751,[Variant]_IDH2:Oncogenic Mutations,7
1752,[Drug]_Enasidenib,7
1753,[Gene]_ACVR1,7
1754,[Variant]_ACVR1:Gain-of-Function,7
1755,[Variant]_ACVR1:G328V,7
1756,[Gene]_H3-3A,7
1757,"[Disease]_Diffuse Midline Glioma, H3 K27M-mutant",3
1758,[Variant]_RET:RET FUSIONS,7
1759,"[Drug]_Avelumab,Nivolumab,Pembrolizumab,Durvalumab,Atezolizumab",6
1760,"[Drug]_Erlotinib,Dacomitinib",7
1761,[Variant]_FGFR3:FGFR3 FUSIONS,7
1762,"[Drug]_Pemetrexed,Docetaxel,Trametinib",7
1763,"[Drug]_Nivolumab,Atezolizumab",4
1764,[Drug]_Immune Checkpoint Inhibitor,7
1765,"[Drug]_Selumetinib,Cetuximab",6
1766,"[Drug]_Erlotinib,Selumetinib",7
1767,"[Drug]_Palbociclib,Binimetinib",7
1768,[Variant]_CHEK1:OVEREXPRESSION,7
1769,"[Drug]_Cisplatin,Prexasertib,Olaparib",7
1770,[Variant]_TP53:G245S,7
1771,[Variant]_TP53:M237I,0
1772,[Variant]_TP53:R158H,2
1773,[Variant]_TP53:V157F,7
1774,[Variant]_TP53:R249S,7
1775,[Variant]_TP53:R280K,7
1776,[Variant]_TP53:R280T,7
1777,[Variant]_TP53:R158L,7
1778,[Variant]_VHL:E46* (c.136G>T),2
1779,[Variant]_VHL:E55* (c.163G>T),0
1780,[Variant]_VHL:Y98H (c.292T>C),7
1781,[Variant]_VHL:H115Q (c.345C>A),7
1782,[Variant]_VHL:F119L (c.357C>G),7
1783,[Variant]_VHL:A149T (c.445G>A),7
1784,[Variant]_VHL:T157I (c.470C>T),7
1785,[Variant]_VHL:R161Q (c.482G>A),7
1786,[Variant]_VHL:R167W (c.499C>T),7
1787,[Variant]_VHL:R167Q (c.500G>A),7
1788,[Variant]_VHL:L178P (c.533T>C),7
1789,[Variant]_VHL:V62fs (c.180del),7
1790,[Variant]_VHL:S65W (c.194C>G),2
1791,[Variant]_VHL:Q73* (c.217C>T),7
1792,[Variant]_VHL:F76del (c.224_226delTCT),4
1793,[Variant]_VHL:N78H (c.232A>C),3
1794,[Variant]_VHL:N78S (c.233A>G),7
1795,[Variant]_VHL:N78T (c.233A>C),7
1796,[Variant]_VHL:S80I (c.239G>T),4
1797,[Variant]_VHL:P86fs (c.254_255insC),7
1798,[Variant]_VHL:P86L (c.257C>T),7
1799,[Variant]_VHL:W88R (c.262T>A),1
1800,[Variant]_VHL:S111FS (c.331delA),5
1801,[Variant]_VHL:S111N (c.332G>A),3
1802,[Variant]_VHL:S111R (c.333C>G),7
1803,[Variant]_EGFR:Gain-of-function,7
1804,[Variant]_VHL:Y112* (c.336C>A),7
1805,[Variant]_VHL:W117C (c.351G>T),7
1806,[Variant]_VHL:L129Q (c.386insAGA),7
1807,[Variant]_VHL:L135* (c.404T>A),0
1808,[Variant]_VHL:N150fs (c.449del),7
1809,[Variant]_VHL:P154fs (c.462delA),7
1810,[Variant]_VHL:C162R (c.484T>C),0
1811,[Variant]_VHL:C162F (c.485G>T),7
1812,[Variant]_VHL:C162W (c.486C>G),7
1813,[Variant]_VHL:V166D (c.497T>A),7
1814,[Variant]_VHL:L184P (c.551T>C),7
1815,[Variant]_VHL:E186* (c.556G>T),7
1816,[Variant]_VHL:E186K (c.556G>A),0
1817,"[Drug]_Fluorouracil,Leucovorin,Trastuzumab",7
1818,[Variant]_VHL:A56fs (c.166_167insA),7
1819,[Variant]_VHL:S65L (c.194C>T),7
1820,[Variant]_VHL:C77fs (c.228dup),7
1821,[Variant]_VHL:R79P (c.236G>C),1
1822,[Variant]_VHL:S80R (c.240T>G),7
1823,[Variant]_VHL:L89P (c.266T>C),7
1824,[Variant]_VHL:G114C (c.340G>T),7
1825,[Variant]_VHL:L118P (c.353T>C),7
1826,[Variant]_VHL:N131fs (c.390_391del),7
1827,[Variant]_VHL:F136S (c.407T>C),7
1828,[Variant]_VHL:L153fs (c.457delC),7
1829,[Variant]_VHL:P154L (c.461C>T),7
1830,[Variant]_VHL:L158V (c.472C>G),7
1831,[Variant]_VHL:V170F (c.508G>T),7
1832,[Variant]_VHL:I180V (c.538A>G),6
1833,[Variant]_VHL:Q195* (c.583C>T),7
1834,"[Drug]_Docetaxel,Erlotinib",7
1835,[Variant]_VHL:V170D (c.509T>A),7
1836,[Variant]_POLE:P286R,7
1837,[Variant]_POLE:V411L,7
1838,[Variant]_POLE:S459F,4
1839,[Variant]_VHL:L116V (c.346C>G),4
1840,[Variant]_VHL:V166F (c.496G>T),7
1841,[Variant]_VHL:S65* (c.194C>A),3
1842,[Variant]_VHL:E70* (c.208G>T),7
1843,[Variant]_VHL:F76S (c.227T>C),7
1844,[Variant]_VHL:L101G (c.301_302delinsGG),5
1845,[Variant]_VHL:T105P (c.313A>C),7
1846,[Variant]_VHL:R107P (c.320G>C),7
1847,[Variant]_VHL:R113* (c.337C>T),1
1848,[Variant]_VHL:L118fs (c.352_353insA),4
1849,[Variant]_VHL:N131T (c.392A>C),7
1850,[Variant]_VHL:T133fs (c.397del),3
1851,[Variant]_VHL:D143fs (c.430delG),7
1852,[Variant]_VHL:R161* (c.481C>T),7
1853,[Variant]_VHL:Q164* (c.490C>T),5
1854,[Variant]_VHL:Y175D (c.523T>G),7
1855,[Variant]_VHL:V181fs (c.540_543del),7
1856,[Variant]_VHL:Y185* (c.555C>G),7
1857,[Variant]_VHL:Q96* (c.286C>T),7
1858,[Variant]_VHL:P86R (c.257C>G),7
1859,[Variant]_VHL:G144* (c.430G>T),7
1860,[Variant]_VHL:L188P (c.563T>C),7
1861,[Variant]_VHL:S111C (c.330_331delinsTT),7
1862,[Variant]_VHL:R64P (c.191G>C),7
1863,[Variant]_VHL:E189fs (c.565del),7
1864,[Variant]_VHL:Splicing alteration (c.340+1G>A),7
1865,[Variant]_VHL:G93S (c.277G>A),7
1866,[Variant]_VHL:I151T (c.452T>C),7
1867,[Variant]_VHL:L158P (c.473T>C),7
1868,[Variant]_VHL:S68P (c.202T>C),7
1869,[Variant]_VHL:Q132P (c.395A>C),1
1870,[Variant]_VHL:Q164R (c.491A>G),6
1871,[Variant]_VHL:E94* (c.280G>T),7
1872,[Variant]_VHL:P103FS (c.309_310delTG),7
1873,[Variant]_VHL:H115P (c.344A>C),7
1874,[Variant]_VHL:L128R (c.383T>G),7
1875,[Variant]_VHL:L169P (c.506T>C),7
1876,[Variant]_VHL:L178R (c.533T>G),1
1877,[Variant]_VHL:M54fs (c.161dup),6
1878,[Variant]_VHL:F91* (c.272_273delinsAA),7
1879,[Variant]_VHL:P59fs (c.176delC),2
1880,[Variant]_VHL:P86S (c.256C>T),7
1881,[Variant]_VHL:S65P (c.193T>C),4
1882,[Variant]_VHL:S72P (c.214T>C),7
1883,[Variant]_VHL:S72fs (c.214del),7
1884,[Variant]_VHL:T124fs (c.369del),3
1885,[Variant]_VHL:L135FS (c.404delT),6
1886,[Variant]_VHL:R176fs (c.526del),7
1887,[Variant]_VHL:R177fs (c.528del),7
1888,[Variant]_VHL:W88* (c.264G>A),7
1889,[Variant]_VHL:V155E (c.464T>A),7
1890,[Variant]_VHL:V170G (c.509T>G),7
1891,[Variant]_VHL:F76fs (c.223_224insT),7
1892,[Variant]_VHL:K196* (c.586A>T),7
1893,[Variant]_VHL:R120G (c.358A>G),7
1894,[Variant]_VHL:R167L (c.500G>T),7
1895,[Variant]_VHL:D126FS (c.375_376insC),7
1896,[Variant]_VHL:E160FS (c.479_480delAG),7
1897,[Variant]_VHL:H115Y (c.343C>T),1
1898,[Variant]_VHL:L153P (c.458T>C),7
1899,[Variant]_VHL:L184R (c.551T>G),7
1900,[Variant]_VHL:L188R (c.563T>G),1
1901,[Variant]_VHL:P138T (c.412C>A),7
1902,"[Drug]_Olaparib,Paclitaxel",7
1903,[Variant]_VHL:Y98C  (c.293A>G),1
1904,[Variant]_VHL:R69fs (c.204insG),7
1905,[Variant]_VHL:Splicing alteration (c.340+5G>C),7
1906,[Variant]_VHL:G144fs (c.432insG),7
1907,[Variant]_VHL:Q145* (c.433C>T),6
1908,[Variant]_VHL:N131K (c.393C>A),7
1909,[Variant]_VHL:T105fs (c.315insAC),7
1910,[Variant]_VHL:P71fs (c.211insT),0
1911,[Variant]_VHL:E52K (c.154G>A),7
1912,[Variant]_VHL:E70K (c.208G>A),3
1913,[Variant]_VHL:H115Q (c.345C>G),7
1914,[Variant]_VHL:H191FS (c.571delC),7
1915,[Variant]_VHL:L140fs (c.417_418delTC),7
1916,[Variant]_VHL:K159fs (c.473dup),7
1917,[Variant]_VHL:P154= (c.462A>C),7
1918,[Variant]_VHL:S80R (c.238A>C),7
1919,[Variant]_VHL:S80N (c.239G>A),7
1920,[Variant]_VHL:R60FS (c.179delG),7
1921,[Variant]_VHL:W88S (c.263G>C),7
1922,[Variant]_VHL:Y156D (c.466T>G),7
1923,[Variant]_VHL:Y156C (c.467A>G),7
1924,[Variant]_VHL:Y156* (c.468T>G),7
1925,[Variant]_VHL:Y175* (c.525C>G),7
1926,[Variant]_VHL:V130L (c.388G>C),6
1927,[Variant]_VHL:G114R (c.340G>C),7
1928,[Variant]_VHL:R177* (c.529A>T),7
1929,[Variant]_VHL:*214L (c.641G>T),7
1930,[Variant]_VHL:*214W (c.642A>G),7
1931,[Variant]_VHL:*214C (c.642A>T),7
1932,"[Drug]_Everolimus,Sunitinib",7
1933,[Variant]_VHL:Splicing alteration (c.464-1G>T),6
1934,"[Drug]_Cetuximab,Panitumumab",7
1935,[Drug]_Imatinib Mesylate,1
1936,[Variant]_PIK3CA:EXON 10 and EXON 21 MUTATIONS,7
1937,[Variant]_VHL:Splicing alteration (c.464-2A>T),7
1938,[Variant]_VHL:R161G (c.481C>G),7
1939,[Variant]_VHL:Splicing alteration (c.463+2T>C),7
1940,[Variant]_VHL:Splicing alteration (c.464-1G>A),7
1941,[Variant]_VHL:Q132* (c.394C>T),7
1942,[Variant]_VHL:C77_N78insL (c.230_231insTCT),7
1943,[Variant]_VHL:L129fs (c.384delT),4
1944,[Variant]_VHL:L178Q (c.533T>A),0
1945,[Variant]_VHL:P81S (c.241C>T),7
1946,[Variant]_VHL:S183* (c.548C>A),7
1947,[Variant]_VHL:Splicing alteration (c.463+1G>C),7
1948,[Variant]_VHL:V74G (c.221T>G),7
1949,[Variant]_VHL:H115R (c.344A>G),1
1950,[Variant]_VHL:R107G  (c.319C>G),7
1951,[Variant]_VHL:R161P (c.482G>C),7
1952,[Variant]_VHL:G93C (c.277G>T),7
1953,[Variant]_VHL:G93V (c.278G>T),7
1954,[Variant]_VHL:L188V (c.562C>G),7
1955,[Variant]_VHL:L198Q  (c.593T>A),7
1956,[Variant]_VHL:F136C (c.407T>G),7
1957,[Variant]_VHL:S65A (c.193T>G),7
1958,[Variant]_VHL:S68W (c.203C>G),7
1959,[Variant]_VHL:Y156N (c.466T>A),7
1960,[Variant]_VHL:P61fs (c.183insC),7
1961,[Variant]_VHL:V84L (c.250G>T),7
1962,[Variant]_VHL:L85P (c.254T>C),7
1963,[Variant]_VHL:G93R (c.277G>C),2
1964,[Variant]_VHL:R108dup (c.322_324dup),1
1965,[Variant]_VHL:D121G (c.362A>G),7
1966,[Variant]_VHL:V194fs (c.581_582del),7
1967,[Variant]_VHL:A149fs (c.449del14-nt),7
1968,[Variant]_VHL:3'UTR alteration (c.639+10C>G),7
1969,[Variant]_VHL:G114S (c.340G>A),7
1970,[Variant]_VHL:W117fs (c.349dup),7
1971,[Variant]_VHL:A122I (c.364_365GC>AT),7
1972,[Variant]_VHL:N150fs (c.445_458del),7
1973,[Variant]_VHL:I151M (c.453C>G),7
1974,[Variant]_VHL:Splicing alteration (c.464-2A>G),7
1975,[Variant]_VHL:L163H (c.488T>A),7
1976,[Variant]_VHL:Y112H (c.334T>C),1
1977,[Variant]_VHL:L128F (c.382C>T),7
1978,[Variant]_VHL:L129P (c.386T>C),7
1979,[Variant]_VHL:C162fs (c.483del),7
1980,[Variant]_VHL:Null (Partial deletion of Exons 2 & 3),7
1981,[Variant]_VHL:N78I (c.233A>T),7
1982,[Variant]_VHL:C162Y (c.485G>A),7
1983,[Variant]_VHL:W88FS (c.263_265delGGCinsTT),7
1984,[Variant]_VHL:K159fs (c.477_478insCA),7
1985,[Variant]_VHL:Q73FS (c.217delC),7
1986,[Variant]_VHL:A149fs (c.445delG),7
1987,[Drug]_JQ-1,7
1988,"[Drug]_Vinorelbine,Docetaxel,Gemcitabine",7
1989,[Variant]_DICER1:E1705K,0
1990,[Disease]_Malignant Sertoli-Leydig Cell Tumor,7
1991,[Variant]_DICER1:D1709N,7
1992,[Variant]_DICER1:E1813Q,7
1993,[Variant]_VHL:P146fs (c.437del),7
1994,[Variant]_VHL:W88R (c.262T>C),7
1995,[Variant]_VHL:H115fs (c.344del),4
1996,[Variant]_VHL:P102fs (c.305delC),7
1997,"[Drug]_Paclitaxel,Vinorelbine,Gemcitabine",7
1998,[Variant]_VHL:R82_V84del (c.243_251del),7
1999,[Variant]_VHL:P40fs (c.118ins),7
2000,[Variant]_VHL:T152fs (c.455insA),7
2001,[Variant]_VHL:T157fs (c.472ins),7
2002,[Variant]_VHL:L158fs (c.471dupT),1
2003,[Variant]_VHL:D92_Y98del (c.275_292del),2
2004,[Variant]_VHL:E160fs (c.477del),7
2005,[Variant]_VHL:V66del (c.197_220del),1
2006,[Variant]_ARID1A:UNDEREXPRESSION,7
2007,[Variant]_VHL:E94FS (c.279delC),7
2008,[Variant]_VHL:G114dup (c.342dupGGT),7
2009,[Variant]_VHL:S65FS (c.194delC),7
2010,[Variant]_VHL:Q73fs (c.214insGCCC),7
2011,[Variant]_VHL:Splicing alteration (c.341-2A>C),7
2012,[Variant]_VHL:G114fs (c.341delCGTTTCCAACAATTTCTCGGTGT),7
2013,[Variant]_VHL:H125fs (c.374insA),7
2014,[Variant]_VHL:K159fs (c.474_476delGAAinsC),7
2015,[Variant]_VHL:Y175* (c.525delC),7
2016,[Variant]_VHL:L188fs (c.562delC),7
2017,[Variant]_VHL:K196fs (c.584_585delAG),7
2018,[Variant]_VHL:D197FS (c.589delG),7
2019,[Variant]_VHL:T202fs (c.606insA),7
2020,[Variant]_VHL:R113FS (c.337delC),7
2021,[Variant]_VHL:A56fs (c.166dup),7
2022,[Variant]_VHL:P61FS (c.182_185delCCGT),7
2023,[Variant]_VHL:Splicing alteration (c.464-1G>C),7
2024,[Variant]_VHL:EXON 3 DELETION,7
2025,[Variant]_VHL:R161= (c.481C>A),7
2026,[Variant]_VHL:I151F (c.451A>T),7
2027,[Variant]_VHL:W88* (c.263G>A),7
2028,[Variant]_VHL:3'UTR alteration (c.642+70C>A),7
2029,[Variant]_VHL:Y98FS (c.291delC),7
2030,[Variant]_VHL:N150S (c.449A>G),6
2031,[Variant]_NRG1:SLC3A2-NRG1,7
2032,[Gene]_RAD50,7
2033,[Variant]_RAD50:L1237F,7
2034,[Disease]_Ureter Small Cell Carcinoma,7
2035,"[Drug]_Irinotecan,Checkpoint Kinase Inhibitor AZD7762",7
2036,[Variant]_BTK:MUTATION,7
2037,[Gene]_PLCG2,7
2038,[Variant]_PLCG2:MUTATION,0
2039,[Drug]_Rilotumumab,7
2040,[Variant]_NRG1:ATP1B1-NRG1,7
2041,[Variant]_NRG1:SDC4-NRG1,7
2042,[Variant]_VHL:R82P (c.245G>C),7
2043,[Variant]_VHL:R177ins (c.531insCTGAGAGTAAAGCCTGAA),7
2044,[Variant]_DICER1:D1709G,1
2045,[Variant]_DICER1:D1709E,7
2046,[Disease]_Glandular Pattern Ovarian Yolk Sac Tumor,3
2047,"[Drug]_Dabrafenib,Trametinib Dimethyl Sulfoxide",7
2048,"[Drug]_Vemurafenib,Panitumumab,Irinotecan",1
2049,[Variant]_EGFR:EGFR-RAD51,7
2050,[Variant]_FGFR2:FGFR2 mutations,7
2051,"[Drug]_Oxaliplatin,Cisplatin",6
2052,"[Drug]_Hyperthermic Intraperitoneal Chemotherapy,Cytoreductive Surgery",7
2053,[Variant]_BAP1:ALTERNATIVE TRANSCRIPT (ATI),7
2054,"[Drug]_Apitolisib,Olaparib",4
2055,"[Drug]_Gemcitabine,Cisplatin,Veliparib",7
2056,"[Drug]_Gemcitabine,Veliparib,Cisplatin",7
2057,[Drug]_Veliparib,7
2058,[Drug]_Iniparib,7
2059,[Variant]_ALK:STRN-ALK,0
2060,[Gene]_BARD1,3
2061,[Variant]_BARD1:LOSS-OF-FUNCTION,7
2062,"[Drug]_Trastuzumab,Capecitabine",7
2063,"[Drug]_Gemcitabine,Trastuzumab",7
2064,[Disease]_Solid Tumor,7
2065,"[Drug]_Paclitaxel,Carboplatin,Buparlisib",7
2066,"[Drug]_Vemurafenib,Pertuzumab",7
2067,[Disease]_Laryngeal Squamous Cell Carcinoma,7
2068,[Variant]_BRAF:G464V,1
2069,[Variant]_BRAF:G469A,7
2070,[Variant]_BRAF:G496A,7
2071,[Variant]_BRAF:N581S,7
2072,[Variant]_BRAF:G466V,7
2073,[Variant]_BRAF:G606E,7
2074,[Variant]_BRAF:P731T,3
2075,[Variant]_BRAF:intron 9 rearrangement,1
2076,[Variant]_BRAF:intron 10 rearrangement,7
2077,[Variant]_BRAF:MACF1-BRAF,7
2078,[Variant]_BRAF:WASFL-BRAF,7
2079,[Variant]_BRAF:CUX1-BRAF,7
2080,"[Drug]_Trastuzumab,Pertuzumab",7
2081,[Disease]_Biliary Tract Cancer,7
2082,"[Drug]_Pertuzumab,Trastuzumab",7
2083,[Disease]_Uterine Cancer,7
2084,[Variant]_ASS1:LOSS,7
2085,"[Drug]_Pegargiminase,Chloroquine",7
2086,[Gene]_BCL2,7
2087,[Variant]_BCL2:MUTATION,7
2088,[Gene]_RASA1,7
2089,[Variant]_RASA1:LOSS-OF-FUNCTION,7
2090,[Gene]_TLK2,7
2091,[Variant]_TLK2:AMPLIFICATION,7
2092,"[Drug]_Go6983,GF109203X",7
2093,[Drug]_U0126,7
2094,[Variant]_BRAF:G469E,4
2095,[Disease]_Ovarian Sex-cord Stromal Tumor,7
2096,[Disease]_Vagina Sarcoma,1
2097,[Disease]_Epithelioid Inflammatory Myofibroblastic Sarcoma,1
2098,"[Drug]_Vemurafenib,Cobimetinib",7
2099,"[Drug]_Encorafenib,Cetuximab",7
2100,"[Drug]_Alpelisib,Encorafenib,Cetuximab",7
2101,[Drug]_Meloxicam,7
2102,[Variant]_VHL:R82_V84del (c.244_252del),0
2103,[Variant]_VHL:L188Q (c.563T>A),7
2104,[Variant]_VHL:A56_P59del (c.166_178del),7
2105,[Variant]_ACVR1:G328E,6
2106,[Variant]_NRG1:NRG1 FUSIONS,5
2107,[Variant]_NTRK2:STRN-NTRK2,1
2108,[Variant]_NTRK1:LMNA-NTRK1,7
2109,[Variant]_NTRK1:TPM3-NTRK1,7
2110,[Variant]_NTRK1:PDE4DIP-NTRK1,7
2111,[Variant]_VHL:G144E (c.431G>A),5
2112,[Disease]_Adrenal Gland Pheochromocytoma,7
2113,[Variant]_VHL:Splicing alteration (c.463+8C>T),7
2114,[Variant]_VHL:G104A (c.311G>C),4
2115,[Variant]_VHL:F91L (c.273C>G),7
2116,[Variant]_VHL:W88fs (c.261dup),7
2117,"[Drug]_Panitumumab,Dabrafenib,Trametinib",7
2118,"[Drug]_Panitumumab,Trametinib",7
2119,[Disease]_Salivary Gland Cancer,7
2120,"[Drug]_Paclitaxel,Trastuzumab",6
2121,"[Drug]_Zoledronic Acid,Trastuzumab,Capecitabine",7
2122,[Variant]_ERBB2:T798I,7
2123,[Variant]_EGFR:R705K,7
2124,[Variant]_EGFR:RARE EGRF MUT,4
2125,[Variant]_ABL1:BCR-ABL T315A,1
2126,"[Drug]_Fluorouracil,Epirubicin,Cyclophosphamide,Paclitaxel,Doxorubicin",7
2127,"[Drug]_Dasatinib,Nilotinib,Imatinib Mesylate",7
2128,[Variant]_ABL1:BCR-ABL L248R,7
2129,"[Drug]_Dasatinib,Imatinib Mesylate",7
2130,[Variant]_ABL1:BCR-ABL F317I,7
2131,[Variant]_ABL1:BCR-ABL F317S,0
2132,[Variant]_ABL1:BCR-ABL F317C,1
2133,[Variant]_AKT1:OVEREXPRESSION,7
2134,[Variant]_BRAF:V600E/K and AMPLIFICATION,7
2135,[Variant]_PIK3R2:OVEREXPRESSION,7
2136,[Gene]_PREX2,7
2137,[Variant]_PREX2:R172I,7
2138,"[Drug]_Imatinib Mesylate,Dasatinib,Nilotinib",7
2139,[Variant]_VHL:3p26.3-25.3 11Mb del,7
2140,[Variant]_ABL1:BCR-ABL E459K,7
2141,[Variant]_ABL1:TKD MUTATION,7
2142,[Variant]_KRAS:G13V,7
2143,[Variant]_VHL:c.128-?_250+?,7
2144,[Variant]_ABL1:P-Loop Mutation,7
2145,[Variant]_ABL1:Non-P-Loop Mutation,7
2146,[Variant]_CSF3R:T618I,7
2147,[Variant]_CALR:MUTATION,7
2148,[Disease]_Essential Thrombocythemia,6
2149,[Variant]_NTRK1:NTRK1-TRIM63,7
2150,[Variant]_NTRK1:NTRK1-DDR2,7
2151,[Variant]_NTRK1:NTRK1-GON4L,7
2152,[Variant]_NTRK2:ETV6-NTRK2,6
2153,[Variant]_BRAF:D594K,0
2154,"[Drug]_Atezolizumab,Pembrolizumab,Nivolumab",0
2155,[Gene]_SDHB,7
2156,[Variant]_SDHB:p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC),7
2157,[Disease]_Paraganglioma,7
2158,[Variant]_H3-3A:K27M,2
2159,[Gene]_H3-3B,2
2160,[Variant]_H3-3B:K36M,7
2161,[Disease]_Chondroblastoma,7
2162,[Variant]_H3-3A:G34W,3
2163,[Disease]_Bone Giant Cell Tumor,7
2164,[Variant]_VHL:c.?213? ?_463 ?del,7
2165,[Variant]_VHL:V87fs (c.259_260insA),7
2166,[Variant]_VHL:c.341-59_341-14del,7
2167,[Variant]_VHL:V166A (c.497T>C),7
2168,[Variant]_VHL:REARRANGEMENT,7
2169,[Variant]_VHL:V66Gfs*89 (c.197_209del),4
2170,[Variant]_VHL:R79_S80del (c.236_241delGCAGTC),1
2171,[Variant]_VHL:P86A (c.256C>G),7
2172,[Variant]_VHL:D92G (c.275A>G),7
2173,[Variant]_VHL:V155G (c.464T>G),7
2174,[Variant]_VHL:Null (Complete deletion),7
2175,[Variant]_VHL:S111C (c.331A>T),7
2176,[Variant]_VHL:G114Vfs*45 (c.339delA),7
2177,[Variant]_VHL:Splicing alteration (c.464-2G>A),1
2178,[Variant]_VHL:Q164L (c.491A>T),7
2179,[Variant]_VHL:R167P (c.500G>C),7
2180,[Variant]_VHL:Y175* (c.525C>A),1
2181,[Variant]_VHL:L178P (c.532C>T),7
2182,[Variant]_VHL:EXON 2 DELETION,7
2183,[Variant]_VHL:EXON 2-3 DELETION,7
2184,[Gene]_PRKCB,7
2185,[Variant]_PRKCB:D427N,7
2186,[Disease]_Adult T-cell Leukemia,7
2187,[Variant]_VHL:*214G (c.640T>G),5
2188,[Variant]_VHL:*214C (c.641_642insC),7
2189,[Gene]_PRPS1,7
2190,[Variant]_HRAS:Q61,7
2191,[Variant]_ABL1:ETV6-ABL1,4
2192,[Variant]_JAK2:GOLGA5-JAK2,1
2193,[Gene]_ABL2,7
2194,[Gene]_NCOA2,7
2195,[Variant]_NCOA2:HEY1-NCOA2,1
2196,[Disease]_Mesenchymal Chondrosarcoma,7
2197,[Gene]_FOXO1,7
2198,[Variant]_FOXO1:PAX3-FOXO1,7
2199,[Disease]_Alveolar Rhabdomyosarcoma,7
2200,[Variant]_FOXO1:PAX7-FOXO1,7
2201,[Variant]_PARP1:OVEREXPRESSION,7
2202,[Drug]_Birabresib,3
2203,[Variant]_JAK2:JAK2 F694L,7
2204,[Disease]_Thyroid Cancer,7
2205,[Drug]_Selpercatinib,5
2206,[Variant]_RET:Oncogenic Mutations,5
2207,[Disease]_Medullary Thyroid Cancer,7
2208,[Variant]_EGFR:V441F,7
2209,"[Drug]_Dasatinib,Imatinib",7
2210,[Variant]_VHL:G104V (c.311G>T),7
2211,[Disease]_Pilocytic Astrocytoma,7
2212,[Variant]_SMARCA4:LOSS,7
2213,"[Drug]_Abemaciclib,Palbociclib",7
2214,[Disease]_Lymphoma,7
2215,[Variant]_TP53:C238Y,7
2216,[Variant]_H3-3A:MUTATION,7
2217,[Disease]_Pediatric Low-grade Glioma,7
2218,[Gene]_MYB,7
2219,[Variant]_ATRX:DELETION,6
2220,[Variant]_CDKN2A:DELETION,7
2221,[Variant]_MYB:AMPLIFICATION,7
2222,"[Drug]_Everolimus,Trametinib",7
2223,[Variant]_FGFR1:INTERNAL DUPLICATION,7
2224,[Variant]_CRLF2:CRLF2-IGH,7
2225,[Disease]_Li-Fraumeni Syndrome,7
2226,[Variant]_ABL1:SNX2-ABL1,7
2227,[Variant]_ABL1:ABL1-RCSD,7
2228,[Variant]_ABL1:ABL1-RCSD1,7
2229,[Variant]_ABL2:ABL2 fusions,1
2230,[Variant]_JAK2:SSBP2-JAK2,7
2231,"[Drug]_Binimetinib,Cetuximab,Encorafenib",3
2232,[Drug]_Tepotinib,7
2233,[Variant]_ROS1:FUSION,7
2234,"[Variant]_FLT3:D835, I836, Internal tandem duplication",7
2235,[Drug]_Gilteritinib,7
2236,"[Drug]_Binimetinib,Encorafenib",7
2237,[Variant]_KIT:V555_V559DEL,7
2238,[Variant]_KIT:K550_K559DEL,7
2239,[Variant]_ABL1:FOXP1-ABL1,7
2240,[Variant]_CDKN2A:MUTATION,7
2241,"[Drug]_Alpelisib,Fulvestrant",7
2242,[Drug]_Icotinib,7
2243,"[Drug]_Fulvestrant,Alpelisib",5
2244,"[Drug]_Sorafenib,Sunitinib",7
2245,[Variant]_FGFR1:FGFR1OP2-FGFR1,4
2246,[Variant]_IKZF1:IKZF1 deletion and mutation,7
2247,"[Drug]_Ponatinib,Imatinib",7
2248,"[Drug]_Sunitinib,Ponatinib",7
2249,"[Drug]_Sorafenib,Vemurafenib",7
2250,[Variant]_KIT:A829P,7
2251,"[Drug]_Sunitinib,Imatinib",1
2252,"[Drug]_Doxorubicin,Methotrexate",7
2253,[Variant]_NFE2L2:MUTATION,7
2254,[Drug]_Sapanisertib,7
2255,[Drug]_Vistusertib,1
2256,[Drug]_Agerafenib,1
2257,[Variant]_ALK:CAD-ALK,1
2258,[Variant]_ROS1:GOPC-ROS1,7
2259,[Variant]_NRG1:APP-NRG1,7
2260,[Variant]_MET:R1004G,7
2261,[Variant]_TP53:R282W,6
2262,"[Drug]_Irinotecan,Panitumumab",7
2263,"[Variant]_EGFR:A289V, R108K, T263P",7
2264,[Disease]_Glioma,1
2265,[Variant]_EGFR:Amplification,7
2266,[Drug]_Akt/ERK Inhibitor ONC201,7
2267,[Variant]_BRAF:A728V,7
2268,[Drug]_BRAF Inhibitor,2
2269,"[Drug]_BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor",7
2270,[Variant]_BRAF:V600_K601>E,7
2271,"[Drug]_Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor",6
2272,[Variant]_BRAF:G469,2
2273,[Variant]_BRAF:A598V,7
2274,[Variant]_FGF19:EXPRESSION,7
2275,[Drug]_Fisogatinib,7
2276,[Drug]_Trastuzumab Deruxtecan,7
2277,[Variant]_JAK2:ATF7IP-JAK2,7
2278,[Variant]_JAK2:EBF1-JAK2,7
2279,[Variant]_JAK2:PPFIBP1-JAK2,4
2280,[Variant]_JAK2:STRN3-JAK2,7
2281,[Variant]_JAK2:TPR-JAK2,7
2282,[Variant]_JAK2:ETV6-JAK2,2
2283,[Variant]_JAK2:BCR-JAK2,7
2284,[Variant]_JAK2:PAX5-JAK2,7
2285,[Variant]_JAK2:TERF2-JAK2,7
2286,[Variant]_JAK2:ZNF274-JAK2,7
2287,[Variant]_JAK2:RFX3-JAK2,7
2288,[Variant]_BRCA2:K3226*,7
2289,"[Drug]_Temozolomide,Olaparib",7
2290,[Disease]_Chondrosarcoma,7
2291,[Variant]_BRAF:N486_P490del,7
2292,[Variant]_BRAF:NRF1-BRAF,1
2293,[Variant]_ABL1:BCR-ABL T315V,7
2294,[Variant]_ABL1:BCR-ABL E292L,7
2295,[Variant]_ABL1:BCR-ABL F317R,1
2296,[Variant]_ABL1:BCR-ABL L248R F359I,7
2297,[Disease]_Acute Lymphoblastic Leukemia,7
2298,"[Drug]_Axitinib,Ponatinib",7
2299,"[Drug]_Nilotinib,Imatinib,Dasatinib",7
2300,"[Drug]_Imatinib,Dasatinib,Nilotinib",2
2301,[Variant]_ABL1:BCR-ABL E255K V299L,7
2302,"[Drug]_Ponatinib,Dasatinib",7
2303,[Variant]_CTNNB1:exon 3 mutation,7
2304,[Variant]_DPYD:EXON 11-19 DELETION,7
2305,"[Drug]_Fluorouracil,Leucovorin",7
2306,[Variant]_MET:MET-ATXN7L1,1
2307,[Disease]_Histiocytic And Dendritic Cell Cancer,7
2308,"[Drug]_Dexamethasone,Ribociclib",7
2309,[Disease]_Glioblastoma Proneural Subtype,7
2310,[Variant]_CDK6:EXPRESSION,1
2311,[Variant]_NT5C2:R238W,7
2312,[Variant]_NT5C2:S445F,7
2313,"[Drug]_Thioguanine,Mercaptopurine",3
2314,"[Drug]_Cytarabine,Doxorubicin,Prednisolone,Gemcitabine",7
2315,"[Drug]_Doxorubicin,Gemcitabine,Prednisolone,Cytarabine",7
2316,"[Drug]_Gemcitabine,Prednisolone,Cytarabine,Doxorubicin",7
2317,[Variant]_NT5C2:NT5C2 MUTATION,1
2318,[Variant]_PRPS1:PRPS1 MUTATION,7
2319,[Variant]_PRPS1:A190T,0
2320,[Variant]_VHL:106insR (c.316insGCC),1
2321,[Variant]_PRPS1:T303S,7
2322,[Variant]_PRPS1:L191F,7
2323,[Variant]_PRPS1:D183E,7
2324,[Variant]_PRPS1:K176N,3
2325,[Variant]_PRPS1:N144S,7
2326,[Variant]_PRPS1:S103I,7
2327,[Variant]_PRPS1:S103N,7
2328,[Variant]_PRPS1:S103T,5
2329,"[Drug]_Mercaptopurine,Lometrexol",7
2330,[Variant]_PRPS1:D139G,1
2331,[Variant]_PRPS1:C77S,7
2332,[Variant]_PRPS1:I72V,4
2333,[Variant]_PRPS1:V53A,7
2334,[Variant]_PRPS1:A87T,7
2335,[Variant]_PRPS1:M115T,0
2336,"[Drug]_Asparaginase,Daunorubicin,Methotrexate",7
2337,"[Drug]_Asparaginase,Cytarabine,Methotrexate,Daunorubicin",1
2338,"[Drug]_Methotrexate,Cytarabine,Daunorubicin,Asparaginase",7
2339,"[Drug]_Methotrexate,Cytarabine,Asparaginase,Daunorubicin",2
2340,"[Drug]_Methotrexate,Asparaginase,Daunorubicin",7
2341,[Variant]_ABL1:BCR-ABL E450Q,7
2342,[Variant]_ABL1:BCR-ABL M244V and L364I,7
2343,[Variant]_ABL1:BCR-ABL N146S,7
2344,[Variant]_ABL1:BCR-ABL V298I,7
2345,[Variant]_ABL1:BCR-ABL S438C,7
2346,[Variant]_ABL1:BCR-ABL M388L,7
2347,[Gene]_IL6,7
2348,[Variant]_IL6:OVEREXPRESSION,7
2349,[Disease]_Rhabdomyosarcoma,7
2350,[Drug]_Bazedoxifene,0
2351,[Variant]_CHEK2:R474C c.1420C>T,7
2352,[Variant]_CTNNB1:exon 3 mutations,7
2353,[Variant]_PDGFRA:OVEREXPRESSION,7
2354,[Variant]_PDGFRA:BCR-PDGFRA,7
2355,[Disease]_B-cell Acute Lymphoblastic Leukemia,7
2356,[Variant]_PDGFB:COL1A1-PDGFB,2
2357,[Variant]_PDGFRB:OVEREXPRESSION,6
2358,[Variant]_JAK2:SMU1-JAK2,4
2359,[Variant]_JAK2:OFD1-JAK2,1
2360,[Variant]_JAK2:SNX29-JAK2,7
2361,[Variant]_JAK2:ZNF430-JAK2,7
2362,[Variant]_PIK3CA:V955I,4
2363,[Variant]_ABL1:Double Ph,4
2364,[Variant]_FLT3:D835Y,7
2365,[Drug]_Arsenic Trioxide,3
2366,[Gene]_MYOD1,7
2367,[Variant]_MYOD1:L122R,7
2368,[Disease]_Spindle Cell Rhabdomyosarcoma,7
2369,"[Drug]_Imatinib,Chemotherapy",7
2370,[Variant]_FLT3:Y842C,7
2371,[Drug]_FLT3/ABL/Aurora Kinase Inhibitor KW-2449,7
2372,[Variant]_FLT3:F691L,7
2373,[Variant]_FLT3:D835I,7
2374,"[Drug]_Vemurafenib,Akt Inhibitor MK2206",7
2375,[Variant]_BCL2:F104I,7
2376,[Drug]_Venetoclax,7
2377,"[Drug]_Vemurafenib,Erlotinib",7
2378,[Variant]_ABL1:BCR-ABL Y253F,7
2379,[Variant]_NTRK2:KANK1-NTRK2,7
2380,"[Drug]_Lapatinib,Capecitabine",5
2381,[Variant]_KRAS:Wildtype,7
2382,[Variant]_BCL2:G101V,7
2383,[Disease]_Thanatophoric Dysplasia,7
2384,[Variant]_SMARCB1:LOSS,7
2385,[Disease]_Atypical Teratoid Rhabdoid Tumor,3
2386,[Variant]_ATRX:Loss-of-function,7
2387,"[Drug]_Etoposide,Larotrectinib,Methotrexate",7
2388,[Disease]_Renal Wilms' Tumor,7
2389,[Variant]_ERBB2:Oncogenic Mutations,7
2390,[Drug]_AZD5363,7
2391,[Variant]_EGFR:Exon 20 insertion,7
2392,[Variant]_MAP2K1:Oncogenic Mutations,7
2393,[Variant]_KRAS:G12C,7
2394,[Variant]_ALK:L1196M,7
2395,[Variant]_ALK:I1171N,7
2396,[Variant]_ALK:G1269A,7
2397,[Variant]_ALK:G1202R,5
2398,[Variant]_ALK:C1156Y,7
2399,[Variant]_MET:Y1230H,7
2400,[Drug]_Poziotinib,7
2401,[Gene]_MAP2K2,7
2402,[Drug]_Binimetinib + Ribociclib,3
2403,[Variant]_ESR1:Oncogenic Mutations,7
2404,"[Drug]_AZD9496, Fulvestrant",0
2405,[Drug]_Selumetinib + Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol,7
2406,[Disease]_Low-Grade Serous Ovarian Cancer,7
2407,"[Drug]_Trametinib, Cobimetinib",7
2408,[Variant]_NF1:Oncogenic Mutations,7
2409,"[Drug]_Cobimetinib, Trametinib",7
2410,[Variant]_BRAF:Fusions,4
2411,[Gene]_KDM6A,7
2412,"[Variant]_MTOR:E2014K, E2419K",7
2413,"[Variant]_FGFR3:G380R, K650, S371C",7
2414,"[Drug]_BGJ398, Debio1347, AZD4547",0
2415,"[Drug]_AZD4547, BGJ398, Debio1347, Erdafitinib",6
2416,[Variant]_PIK3CA:Oncogenic Mutations,7
2417,[Drug]_GDC-0077,7
2418,[Drug]_Copanlisib + Fulvestrant,0
2419,"[Drug]_Debio1347, BGJ398, AZD4547",6
2420,[Variant]_ABL1:T315I,7
2421,"[Variant]_ABL1:E255K, E255V, F359C, F359I, F359V, Y253H",7
2422,[Drug]_Asciminib,7
2423,[Drug]_AMG-510,4
2424,[Variant]_PDGFRA:FIP1L1-PDGFRA Fusion,7
2425,[Variant]_HRAS:Oncogenic Mutations,7
2426,[Disease]_Head and Neck Squamous Cell Carcinoma,7
2427,[Drug]_Tipifarnib,7
2428,[Drug]_Pralsetinib,7
2429,[Variant]_BRAF:L597,7
2430,"[Drug]_BGJ398, AZD4547, Debio1347",6
2431,[Variant]_BRAF:K601,7
2432,[Variant]_KIT:D816,0
2433,[Disease]_Mastocytosis,7
2434,"[Variant]_PDGFRA:D842V, D842Y, D842_H845del, D842_H845insV",7
2435,[Drug]_Avapritinib,7
2436,"[Drug]_AZD4547, BGJ398, Erdafitinib, Debio1347",5
2437,[Drug]_RO5045337,6
2438,[Drug]_Milademetan Tosylate,4
2439,[Drug]_Encorafenib + Panitumumab,7
2440,[Variant]_PDGFRA:Oncogenic Mutations,4
2441,"[Variant]_KIT:A829P, C809G, D816, D820, N822, Y823D",7
2442,[Drug]_Ripretinib,7
2443,[Variant]_KIT:V654A,0
2444,"[Variant]_KIT:D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 deletion, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY",7
2445,"[Variant]_KIT:A502_Y503dup, K509I, N505I, S476I, S501_A502dup",7
2446,[Disease]_Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma,7
2447,[Drug]_Carboplatin-Taxol Regimen + Trastuzumab,7
2448,[Disease]_Ganglioglioma,3
2449,"[Drug]_Vemurafenib + Cobimetinib, Dabrafenib + Trametinib",7
2450,[Drug]_Trastuzumab + Pertuzumab,7
2451,[Drug]_Lapatinib + Trastuzumab,7
2452,[Disease]_Pleomorphic Xanthoastrocytoma,7
2453,"[Drug]_Dabrafenib + Trametinib, Vemurafenib + Cobimetinib",1
2454,[Variant]_KIT:Oncogenic Mutations,3
2455,[Disease]_Thymic Tumor,7
2456,[Variant]_CDK4:Amplification,7
2457,[Disease]_Dedifferentiated Liposarcoma,7
2458,"[Drug]_Palbociclib, Abemaciclib",7
2459,[Disease]_Well-Differentiated Liposarcoma,7
2460,"[Drug]_Abemaciclib, Palbociclib",0
2461,"[Variant]_BRAF:V600E, V600K",6
2462,[Drug]_Encorafenib + Binimetinib,7
2463,[Variant]_BRAF:V600,7
2464,[Drug]_Dabrafenib + Trametinib,7
2465,[Disease]_Anaplastic Thyroid Cancer,7
2466,[Drug]_Vemurafenib + Cobimetinib,7
2467,[Drug]_Ado-Trastuzumab Emtansine,3
2468,[Gene]_BRIP1,7
2469,[Variant]_BRIP1:Oncogenic Mutations,4
2470,[Gene]_FANCL,1
2471,[Variant]_FANCL:Oncogenic Mutations,7
2472,[Disease]_Neurofibroma,7
2473,[Variant]_FGFR3:Oncogenic Mutations,7
2474,[Variant]_PTEN:Oncogenic Mutations,7
2475,[Variant]_FGFR1:Oncogenic Mutations,7
2476,[Variant]_MET:Fusions,7
2477,"[Variant]_BRAF:G464, G469A, G469R, G469V",1
2478,[Variant]_CDK12:Truncating Mutations,1
2479,[Variant]_FGFR2:Oncogenic Mutations,7
2480,[Variant]_CDKN2A:Oncogenic Mutations,7
2481,[Variant]_MTOR:Oncogenic Mutations,7
2482,[Gene]_Other Biomarkers,1
2483,[Drug]_Niraparib,7
2484,[Gene]_RAD51B,7
2485,[Variant]_RAD51B:Oncogenic Mutations,1
2486,[Variant]_CDK12:Oncogenic Mutations,7
2487,[Gene]_RAD51C,7
2488,[Variant]_RAD51C:Oncogenic Mutations,7
2489,[Variant]_ATM:Oncogenic Mutations,7
2490,[Drug]_Encorafenib + Cetuximab,7
2491,[Drug]_Pertuzumab + Trastuzumab,7
2492,[Drug]_Trastuzumab + Lapatinib,7
2493,[Variant]_BARD1:Oncogenic Mutations,1
2494,[Drug]_Capecitabine + Trastuzumab + Tucatinib,7
2495,[Variant]_RAD51D:Oncogenic Mutations,7
2496,[Gene]_RAD54L,1
2497,[Variant]_RAD54L:Oncogenic Mutations,7
2498,[Disease]_Erdheim-Chester Disease,7
2499,[Variant]_FLT3:Oncogenic Mutations,7
2500,[Drug]_Midostaurin + High Dose Chemotherapy,7
2501,[Drug]_Vemurafenib + Atezolizumab + Cobimetinib,7
2502,[Drug]_Ipilimumab + Nivolumab,7
2503,[Drug]_Fulvestrant + Alpelisib,7
2504,[Variant]_TSC1:Oncogenic Mutations,7
2505,[Disease]_CNS Cancer,7
2506,[Variant]_TSC2:Oncogenic Mutations,7
2507,[Variant]_CHEK1:Oncogenic Mutations,1
2508,[Variant]_PDGFRA:Fusions,7
2509,[Disease]_Myelodysplastic/Myeloproliferative Neoplasms,7
2510,[Variant]_PDGFRB:Fusions,7
2511,[Drug]_Pemigatinib,7
2512,[Variant]_PALB2:Oncogenic Mutations,7
2513,[Variant]_CHEK2:Oncogenic Mutations,1
2514,"[Drug]_Gefitinib, Afatinib, Erlotinib",7
2515,"[Drug]_Bosutinib, Nilotinib, Imatinib, Dasatinib",7
2516,[Variant]_BTK:C481S,7
2517,[Disease]_Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,7
2518,"[Drug]_Erlotinib, Afatinib, Gefitinib",7
2519,"[Drug]_Cetuximab, Panitumumab",7
2520,"[Drug]_Panitumumab, Cetuximab",7
2521,"[Drug]_Bosutinib, Dasatinib, Imatinib, Nilotinib",3
2522,[Drug]_H3B-8800,6
2523,[Disease]_Myelodysplastic Syndromes,7
2524,[Variant]_FLI1:EWSR1-FLI1 Fusion,7
2525,[Disease]_Ewing Sarcoma of Soft Tissue,7
2526,[Drug]_TK216,6
2527,"[Drug]_Temsirolimus, Everolimus",0
2528,[Drug]_PLX8394,1
2529,"[Drug]_Abemaciclib, Ribociclib, Palbociclib",7
2530,"[Drug]_BGJ398, Erdafitinib, AZD4547, Debio1347",7
2531,"[Drug]_Pembrolizumab, Cemiplimab, Nivolumab",7
2532,"[Drug]_Binimetinib, Trametinib, Cobimetinib",7
2533,"[Drug]_Debio1347, Erdafitinib, BGJ398, AZD4547",7
2534,"[Drug]_AZD8186, GSK2636771",7
2535,"[Drug]_AZD4547, Erdafitinib, Debio1347, BGJ398",7
2536,"[Drug]_Crizotinib, Capmatinib",7
2537,[Variant]_KIT:D820,7
2538,"[Drug]_Erlotinib, Osimertinib, Gefitinib",7
2539,[Variant]_KIT:N822,0
2540,"[Drug]_Capmatinib, Crizotinib, Cabozantinib",7
2541,[Variant]_JAK2:V617F,7
2542,[Disease]_Lymphoid Leukemia,4
2543,[Variant]_PDGFRA:D842V,1
2544,[Variant]_DNMT3A:R882,7
2545,[Gene]_NPM1,7
2546,[Gene]_WT1,1
2547,[Gene]_TET2,7
2548,[Disease]_Bone Marrow Cancer,7
2549,[Variant]_KRAS:G12,7
2550,[Disease]_Acute Leukemia,7
2551,[Variant]_NRAS:Q61,7
2552,[Drug]_Daunorubicin,0
2553,[Variant]_MAP2K1:P124S,7
2554,[Drug]_Selumetinib,7
2555,[Variant]_MAP2K1:Q56P,7
2556,[Drug]_Vemurafenib,7
2557,[Disease]_Thyroid Gland Papillary Carcinoma,7
2558,[Drug]_Imatinib,6
2559,[Disease]_Malignant Anus Melanoma,7
2560,[Variant]_ARAF:S214C,7
2561,[Gene]_DDR2,7
2562,[Drug]_Sorafenib,0
2563,[Drug]_Idarubicin,7
2564,[Disease]_Polycythemia Vera,7
2565,[Drug]_Fedratinib,7
2566,[Variant]_NRAS:G13D,7
2567,[Drug]_Tanespimycin,7
2568,[Variant]_NRAS:Q61L,5
2569,[Drug]_Temozolomide,7
2570,[Variant]_NRAS:Q61R,7
2571,[Variant]_KIT:D816V,7
2572,[Variant]_NRAS:MUTATION,7
2573,[Gene]_APC,7
2574,[Variant]_ALK:F1174L,7
2575,[Drug]_Crizotinib,6
2576,[Disease]_Diffuse Large B-cell Lymphoma,0
2577,[Variant]_KIT:L576P,7
2578,"[Drug]_Nilotinib,Imatinib,Sorafenib",7
2579,[Variant]_KRAS:G12/G13,7
2580,"[Drug]_Gefitinib,Erlotinib",7
2581,"[Drug]_Chemotherapy,Cetuximab",7
2582,[Drug]_Alectinib,1
2583,[Variant]_ALK:R1275Q,7
2584,[Drug]_TAE684,7
2585,[Drug]_Trametinib,7
2586,[Drug]_Dasatinib,7
2587,[Variant]_PDGFRA:D842I,7
2588,[Drug]_Crenolanib,7
2589,[Variant]_PDGFRA:D842Y,7
2590,[Variant]_PDGFRA:I843DEL,7
2591,[Variant]_PDGFRA:D842_I843delinsVM,7
2592,[Variant]_FLT3:ITD,2
2593,[Variant]_KIT:EXON 11 MUTATION,7
2594,[Variant]_NRAS:G12,7
2595,[Variant]_KIT:EXON 14 MUTATION,0
2596,[Variant]_BRAF:V600E and V600M,7
2597,[Drug]_Dabrafenib,7
2598,[Variant]_RET:M918T,0
2599,[Variant]_RET:C634W,7
2600,[Drug]_Motesanib,7
2601,[Drug]_JAK2 Inhibitor AZD1480,5
2602,[Variant]_PIK3CA:E542K,7
2603,[Drug]_Regorafenib,7
2604,"[Drug]_MEK Inhibitor PD0325901,Trametinib",7
2605,[Variant]_KRAS:EXON 2 MUTATION,7
2606,[Drug]_Panitumumab,1
2607,"[Drug]_Panitumumab,Sorafenib",1
2608,[Variant]_BRAF:V600E and AMPLIFICATION,2
2609,"[Drug]_Dabrafenib,Trametinib",7
2610,[Variant]_BRAF:V600D,7
2611,"[Drug]_Pictilisib Bismesylate,PLX4720",0
2612,"[Drug]_PLX4720,Nutlin-3",7
2613,"[Drug]_Capecitabine,Bevacizumab,Vemurafenib",0
2614,[Variant]_NPM1:EXON 12 MUTATION,3
2615,[Variant]_NPM1:W288FS,7
2616,[Variant]_CEBPA:MUTATION,7
2617,[Drug]_Tretinoin,7
2618,[Variant]_PIK3CA:EXON 10 MUTATION,7
2619,[Drug]_Cetuximab,7
2620,[Disease]_Hematologic Cancer,7
2621,[Drug]_SU5614,7
2622,[Variant]_KRAS:G12V,7
2623,[Variant]_PIK3CA:EXON 21 MUTATION,7
2624,[Variant]_WT1:EXON 7 MUTATION,1
2625,"[Drug]_Cytarabine,Daunorubicin",7
2626,[Variant]_ALK:EML4-ALK L1196M,7
2627,[Variant]_FGFR3:FGFR3-BAIAP2L1,7
2628,[Drug]_PD173074,7
2629,[Variant]_KRAS:G13D,7
2630,[Drug]_Valproic Acid,7
2631,"[Drug]_Tretinoin,NSC348884",7
2632,"[Drug]_Anti-CD33,Anti-CD123",7
2633,[Drug]_Anti-CD33,7
2634,[Drug]_NSC348884,6
2635,[Drug]_Induction Therapy,7
2636,[Variant]_TSC1:FRAMESHIFT TRUNCATION,7
2637,[Drug]_Sirolimus,7
2638,[Disease]_Clear Cell Renal Cell Carcinoma,2
2639,[Variant]_TSC1:LOSS-OF-FUNCTION,7
2640,[Drug]_Everolimus,7
2641,[Disease]_Invasive Bladder Transitional Cell Carcinoma,7
2642,[Variant]_FLT3:MUTATION,7
2643,[Variant]_IDH1:R132,7
2644,[Variant]_WT1:EXON 9 MUTATION,7
2645,[Variant]_FLT3:TKD MUTATION,7
2646,[Variant]_MGMT:PROMOTER METHYLATION,4
2647,[Variant]_DNMT3A:MUTATION,7
2648,[Variant]_BRCA1:LOSS-OF-FUNCTION,7
2649,[Drug]_Olaparib,7
2650,[Variant]_BRCA2:LOSS-OF-FUNCTION,7
2651,[Variant]_ABL1:BCR-ABL,7
2652,[Variant]_U2AF1:Q157P/R,7
2653,[Variant]_U2AF1:S34Y/F,7
2654,[Gene]_CCND2,7
2655,[Variant]_CCND2:PROMOTER DEMETHYLATION,7
2656,[Variant]_CCND1:OVEREXPRESSION,7
2657,[Variant]_IDH1:R132C,7
2658,[Variant]_KRAS:G12D,7
2659,[Variant]_EGFR:L858R,7
2660,[Drug]_Akt Inhibitor MK2206,7
2661,[Variant]_ABL1:BCR-ABL E255K,7
2662,[Variant]_ABL1:BCR-ABL T315I,7
2663,[Variant]_ALK:EML4-ALK C1156Y,2
2664,[Drug]_Erlotinib,1
2665,[Drug]_Gefitinib,7
2666,[Drug]_Dacomitinib,7
2667,[Variant]_ERBB2:L755S,7
2668,[Drug]_Lapatinib,7
2669,[Variant]_ESR1:L536Q,7
2670,[Drug]_Hormone Therapy,7
2671,[Variant]_ESR1:D538G,7
2672,[Variant]_ESR1:Y537C,7
2673,[Variant]_ESR1:Y537N,3
2674,[Variant]_ESR1:Y537S,0
2675,[Variant]_KRAS:G12A,7
2676,[Gene]_GATA2,7
2677,[Variant]_PIK3CA:H1047R,4
2678,"[Drug]_Panitumumab,Cetuximab",7
2679,"[Drug]_Dasatinib,Nilotinib",6
2680,[Variant]_ALK:EML4-ALK,7
2681,[Gene]_CCND3,7
2682,[Variant]_CCND3:LOSS,7
2683,[Disease]_T-cell Lymphoblastic Leukemia/lymphoma,7
2684,[Drug]_Palbociclib,7
2685,[Variant]_CDK4:EXPRESSION,7
2686,[Drug]_Alpelisib,7
2687,[Variant]_DDR2:G253C,6
2688,[Variant]_DDR2:G505S,1
2689,[Variant]_DDR2:G774V,7
2690,[Variant]_DDR2:I638F,7
2691,[Variant]_DDR2:L239R,1
2692,[Variant]_DDR2:L63V,7
2693,[Variant]_DDR2:S768R,7
2694,"[Drug]_Dasatinib,Erlotinib",7
2695,[Variant]_EGFR:EXON 19 DELETION,7
2696,[Variant]_EGFR:G719S,7
2697,"[Drug]_Pemetrexed,Erlotinib",7
2698,[Drug]_Staurosporine,7
2699,[Variant]_ERBB2:D769H,7
2700,"[Drug]_Lapatinib,Neratinib",7
2701,[Variant]_ERBB2:D769Y,7
2702,[Drug]_Neratinib,7
2703,[Variant]_ERBB2:L755_T759del,7
2704,[Variant]_ERBB2:G309A,7
2705,[Variant]_ERBB2:L755W,7
2706,[Variant]_ERBB2:P780INS,7
2707,[Variant]_ERBB2:R678Q,7
2708,[Variant]_ERBB2:R896C,2
2709,[Variant]_ERBB2:V777L,7
2710,[Variant]_ERBB2:V842I,7
2711,"[Drug]_Tamoxifen,Fulvestrant",7
2712,"[Drug]_Fulvestrant,Tamoxifen",7
2713,[Variant]_FGFR2:FGFR2-MGEA5,7
2714,[Drug]_Ponatinib,1
2715,[Variant]_FGFR2:FGFR2-TACC3,7
2716,"[Drug]_Pazopanib,Ponatinib",7
2717,[Drug]_Lestaurtinib,7
2718,[Drug]_Tyrphostin AG 1296,7
2719,[Variant]_GATA2:EXPRESSION,7
2720,"[Drug]_Bortezomib,Fasudil",7
2721,[Variant]_KIT:INTERNAL DUPLICATION,1
2722,"[Drug]_Dasatinib,Nilotinib,Imatinib",7
2723,[Drug]_Sunitinib,7
2724,"[Drug]_Dactolisib,Selumetinib",7
2725,[Drug]_Carmustine,7
2726,[Drug]_O6-Benzylguanine,7
2727,[Drug]_PI3K-alpha Inhibitor MEN1611,7
2728,[Variant]_PML:PML-RARA,7
2729,[Variant]_PTEN:R233*,7
2730,[Drug]_MTOR Inhibitor,7
2731,[Variant]_TP53:R175H,7
2732,[Drug]_Doxorubicin,7
2733,[Variant]_IDH2:R140,7
2734,[Variant]_IDH2:MUTATION,7
2735,[Disease]_Myelodysplastic Syndrome,7
2736,[Variant]_IDH2:R172K,7
2737,[Variant]_CCND1:EXPRESSION,7
2738,[Variant]_SF3B1:MUTATION,7
2739,[Variant]_CCND1:AMPLIFICATION,7
2740,[Variant]_CCND2:OVEREXPRESSION,7
2741,[Variant]_CCNE1:OVEREXPRESSION,7
2742,[Disease]_Gastric Adenosquamous Carcinoma,7
2743,[Variant]_CDKN2A:PROMOTER HYPERMETHYLATION,7
2744,[Variant]_NOTCH1:D1642H,7
2745,[Variant]_NOTCH1:R2327W,3
2746,[Variant]_NOTCH1:S2275FS,7
2747,[Variant]_NOTCH1:V2444FS,6
2748,[Variant]_PIK3CA:E545K,7
2749,[Variant]_TP53:R248Q,7
2750,[Variant]_TP53:R248W,2
2751,[Variant]_TP53:R249,7
2752,[Variant]_TP53:R273C,7
2753,[Variant]_TP53:R273H,6
2754,[Gene]_CSF1R,7
2755,[Variant]_CSF1R:MEF2D-CSF1R,7
2756,"[Drug]_GW-2580,Imatinib",7
2757,[Variant]_PRKACA:DNAJB1-PRKACA,7
2758,[Disease]_Fibrolamellar Carcinoma,7
2759,[Variant]_BCL2:IGH-BCL2,7
2760,[Gene]_REL,7
2761,[Gene]_FOXP1,7
2762,[Variant]_FOXP1:AMPLIFICATION,7
2763,[Variant]_REL:AMPLIFICATION,7
2764,[Variant]_RUNX1:MUTATION,7
2765,[Drug]_Cytarabine,7
2766,[Gene]_IGF2,7
2767,[Variant]_IGF2:OVEREXPRESSION,7
2768,[Drug]_Linsitinib,7
2769,"[Drug]_Linsitinib,Cabazitaxel,Docetaxel",7
2770,[Variant]_TET2:MUTATION,7
2771,[Variant]_AURKA:EXPRESSION,7
2772,[Variant]_VHL:MUTATION,7
2773,[Variant]_PBRM1:MUTATION,3
2774,[Variant]_BCL2:EXPRESSION,7
2775,[Variant]_EZH2:MUTATION,7
2776,[Variant]_VHL:LOSS-OF-FUNCTION,7
2777,[Variant]_FLI1:EWSR1-FLI1 Type 1,1
2778,[Variant]_EZH2:Y646,7
2779,[Gene]_KMT2D,7
2780,[Variant]_KMT2D:LOSS-OF-FUNCTION,7
2781,[Drug]_Ibrutinib,7
2782,[Variant]_AKT1:Q79K,7
2783,[Variant]_ALK:EML4-ALK and AMPLIFICATION,4
2784,[Variant]_ALK:ALK FUSION G1202R,7
2785,[Variant]_ALK:EML4-ALK S1206Y,7
2786,[Variant]_ALK:EML4-ALK T1151INST,7
2787,[Variant]_APC:MUTATION,7
2788,[Disease]_Colon Carcinoma,7
2789,[Drug]_JW55,7
2790,[Drug]_G007-LK,7
2791,[Variant]_AR:F877L,2
2792,"[Drug]_Apalutamide,Enzalutamide",7
2793,[Variant]_AR:W742,7
2794,[Disease]_Prostate Carcinoma,7
2795,[Drug]_Bicalutamide,7
2796,[Variant]_ASXL1:MUTATION,7
2797,[Variant]_ATM:MUTATION,1
2798,[Variant]_ATM:UNDEREXPRESSION,7
2799,"[Drug]_NU7441,KU-0060648",7
2800,[Variant]_AURKA:AMPLIFICATION,7
2801,[Disease]_Esophagus Adenocarcinoma,7
2802,"[Drug]_Cisplatin,Alisertib",7
2803,[Variant]_AURKA:OVEREXPRESSION,7
2804,[Disease]_Cervical Adenocarcinoma,7
2805,[Drug]_Paclitaxel,7
2806,[Variant]_BAP1:EXPRESSION,7
2807,[Variant]_BAP1:MUTATION,7
